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ABSTRACT 
 
 
Diabetes mellitus is one of risk factors that contributes to the development of 
dyslipidemia, which is a leading cause of coronary heart disease in adult life.The aims 
of the study were to determine the prevalence of dyslipidemia in children with type 1 
diabetes and to study the correlation between dyslipidemia and some of the risk 
factors. A cross sectional prospective hospital based study was carried out during the 
period from August 2004 to January 2005.  The study was conducted at Gaffer Ibn 
Auf Children Emergency Hospital, Ahmed Gasim Teaching Hospital and Gabir Abu 
Aleiz Diabetes Center. 
Two hundred children were enrolled in the study; one hundred diabetics and 
their controls matched according to sex and age group (mean age of diabetics 12.0 ± 
3.6SD and 12.1 ± 2.5SD for control). The prevalence of dyslipidemia in the fasting 
state was increased in the diabetic group (43%) compared to control group (21%). 
Hypercholesterolemia was found in 10% of diabetic group and hypertriglyceridemia 
in 16%, compared to 4% and 7% respectively in control group. Dyslipidemia of LDL 
was 26% in diabetics and 2% of controls while HDL was found low in 2% of diabetics 
and none of controls.  Positive correlation was found between dyslipidemia and 
glcosylated HbA1c, duration of diabetes and exercise. 
In Conclusion: lipid abnormalities remain common in children with type 1 
diabetes and need to be screened for.  
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1. INTRODUCTION AND LITERATURE REVIEW 
 1.1 Historical Background and Definition of Diabetes 
        1.1.1. Historical background: 
 The name diabetes is derived from the Greek word diabeniein 
which means excess. It was described in the first century AD by the 
Greek physician Aretaeus, pointing to the polyuria which characterizes 
the condition. Later in the fifth century Susruta recognized the 
sweetness of urine of diabetic patients and the Latin word mellitus –
honey – was added.  
 Paul Langerhans a young German medical student described the 
anatomy of islet cells in 1888 and their endocrine secretion was 
summarized 4 years later by Langnese. The comprehensive theory of 
diabetes mellitus was advanced by Nauny in 1898.The active agent 
insulin was isolated by the collaborative work of the Toronto group in the 
year 1921 and used in humans in the year 1922. The Toronto group was 
awarded the Nobel Prize for this discovery in 1923 (1). 
 1.1.2. Definition: 
             The term (DM) comprises a heterogeneous group of 
hyperglycemic disorders as   a result of relative or absolute deficiency of 
insulin, along with varying degrees of peripheral resistance to the action 
of insulin and a relative or absolute excess of glucagon (2) 
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1.1.3 New classification:                                                                
          Every new year the diabetes community re-evaluates the current 
recommendation for the classification, diagnosis and screening of 
diabetes, reflecting new information from research and clinical practice. 
New recommendations were announced at the American Diabetes 
Association (ADA) meeting in Boston in June 1997 (3).                               
 In this classification there is no distinction between primary and 
secondary causes of diabetes. The terms type 1 and type 2 diabetes are 
to be used, whereas, terms like insulin dependent, non insulin 
dependent, juvenile onset, maturity onset, adult onset, and maturity 
onset diabetes of the young (MODY) are to be eliminated. This change 
reflects an attempt to classify diabetes according to etiologic differences 
and to move away from describtions based upon age at onset or type of 
treatment.                                                                                          
          In type 1 diabetes the majority of patients have autoimmune 
destruction of the pancreatic beta cells. This is termed type1A to 
distinguish it from some rare cases in which an autoimmune etiology 
cannot be determined i.e. idiopathic, which is termed type 1B.  Type 1A 
patients have an absolute requirement of insulin therapy and will 
develop (DKA) if not given insulin. However, some patients with type 1 
diabetes will not meet all of these criteria e.g. those who pass through a 
transient non insulin dependent "Honey moon" period (2, 3).                                                
- 19  - 
 
            Type 2 diabetes is by far the most common type of diabetes. 
Patients don't have autoimmune destruction of beta cells, pancreatic 
disease or other rare causes of hyperglycemia. They have sufficient 
endogenous insulin production to prevent (DKA) and variable degrees of 
insulin resistance, though some patients develop (DKA) under certain 
circumstances and may require treatment with insulin (3, 4).                                     
1.1.4 Diagnosis of diabetes mellitus: 
    1.1.4.1. Modalities of diagnosis: 
            • Fasting plasma glucose (FPG): 
      Fasting blood glucose is an elevated plasma glucose level after an 
over night fast and is regarded as the gold standard for diagnosis. The 
diagnostic value was 7.8 mmol/l or higher on at least two occasions in 
the old criteria, but the ADA recommended a lower level of 7 mmol/l (2). 
          • Oral glucose tolerance test (OGTT):  
             This is performed in the morning after an over night fast by 
taking plasma glucose sample as pretest. At 0 minute giving 1.75 g/kg 
oral glucose and measuring blood glucose at 1 and 2 hour (2, 5). 
           Various diagnostic standards for diabetes have been 
recommended. The most sensitive but not specific for diagnosis  are 
those of Mosenthal and Barry and the most specific diagnostic criteria 
are those of the National Diabetes Data Group (NDDG) which was 
previously  known as  the old criteria.  
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 Glucose levels recommended as   diagnostic for diabetes by 
OGTT are shown below (6): 
Time after ingestion        Manthesal-Barry       Fajans-Conn        NDDG 
1 hour                              9.2 mmol/l               10.3 mmol/l       11.1 mmol/l 
2 hours                            6.4 mmol/l                7.8 mmol/l        11.1 mmol/l 
Interpretation of the OGTT is as follows: 
1- Fasting plasma glucose > 7 mmol/l or 2 hours concentration >11.1 
mmol/l are diagnostic of diabetes. 
2- Two hours plasma glucose > 7.8mmol/l and < 11 mmol/l suggests 
impaired fasting glycemia. 
3- Fasting plasma glucose > 6 but < 7 mmol/l suggests impaired fasting 
glycemia.  
       Oral glucose tolerance test is indicated for confirmation of the 
diagnosis of diabetes in uncertain cases with borderline blood glucose 
concentration (e.g. in sibling of diabetic patient or in children with cystic 
fibrosis prone to diabetes) and for diagnosis of impaired glucose 
tolerance. When used for screening in large populations, the test 
overestimates the prevalence of diabetes (1, 6).    
               • Glycated Hemoglobin (Hb A1C):  
          There had been interest in the use of HbA1c values for screening 
and identification of impaired glucose tolerance and diabetes. An 
increased level of Hb A1C constitutes presumptive evidence of diabetes, 
- 21  - 
 
though a normal HbA1c level doesn't exclude impaired glucose 
tolerance or mild diabetes (1, 5).  Hb A1c determinations correlate with the 
fasting plasma glucose level, so their values may be considered in 
combination. In one cross sectional analysis of two large data sets, 60% 
of patients with diabetes diagnosed by the new fasting blood glucose 
criteria had a normal HbA1c value as compared to 19% of those 
diagnosed by the old criteria. Upon  these findings  diabetes  should not 
be diagnosed  in patients with fasting blood glucose < 7.8 mmol/l unless 
the Hb A1c was also high, and  patients with normal HbA1c value and 
fasting blood glucose between 6.1- 7.7 mmol/l  should be given the 
diagnosis of impaired fasting glucose. However, there remain serious 
problems in the standardization of HbA1c assays. Thus at the present 
time the diagnosis of diabetes mellitus should not be made on basis of 
HbA1c values alone (7, 8). 
              • Acute Insulin Response to glucose (AIRg):  
      In this test glucose is infused as 25%solution for 3 minutes at a total 
load of 0.5g/kg; then plasma insulin is measured at 1 and 3 minutes, and 
values above baseline are added. Sums below 48 micro unit/ml   are 
predictive of diabetes, especially if the subject is islet cell cytoplasmic 
antibody    positive (9).     
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1.1.4.2. New criteria: 
              The new criterion strongly suggest that the diagnosis of 
diabetes be made on the basis of fasting blood glucose only .A 
provisional report from the (WHO) agreed with the new definitions, but 
suggests continued use of the (OGTT) for patients with blood glucose 
values in the uncertain range (10). The following definitions have been 
suggested (3, 10):                                                                                                                                                      
-  Normal -- FPG < 6.1 mmol/L.                                                                 
-  Impaired -- FPG between 6.1- 6.9 mmol /l. 
- Diabetes mellitus -- FBG above 7mmol/L or symptoms of diabetes and 
random blood glucose at or above 11.1mmol/L confirmed on another 
occasion. 
           The shift from using 2h value on an (OGTT) to (FPG) causes 
change in the prevalence of (DM), depending on the population studied. 
In one report the old criteria were more likely to diagnose diabetes    in 
lean subjects, while the new criteria were more likely to identify it in 
middle aged obese subjects. In another review almost twice as many 
subjects were classified as diabetic by the new than the old fasting 
criteria (11).  
         The prognostic impact of these changes in subjects at risk of 
developing microvascular or macrovascular complications is not known, 
although data are accumulating that the old criteria were better 
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predictors of cardiovascular risk and mortality. In a study over 25,000 
patients followed for 7yrs, the 2 hour values of the (OGTT) were 
predictive of high mortality while the fasting blood glucose was not (12). 
 1.2. Pathogenesis and Epidemiology of Type 1 Diabetes             
        1.2.1. Epidemiology: 
             1.2.1.1. Prevalence:                                                                                                    
                      Type 1 diabetes mellitus is predominantly a disease of 
whites and of populations with a substantial white genetic admixture, 
including African American. In the United States the prevalence among 
school aged children is about 1.9/1000 and 1 in 360 in children at 16 
years. In Finland the prevalence is nearly 40 in 100.000 and 1 in 
100,000 in Japan. These differences may not be entirely racial, because 
there may be regional differences in prevalence within the country. An 
environmental impact is also suggested by seasonal variations in rate of 
appearance, and by the fact that fewer than half of identical twins are 
concordant for IDDM (13). 
        1.2.1.2. Incidence: 
            Major world-wide variations in incidence exist. The United States 
have intermediate incidence of about 12-15 new cases / 100,000. In 
Korea, China and Mexico the incidence is 0.6/100,000 per year 
compared to 38.4/100,000 per year in Finland. These observations have 
implication for genetic counseling.  
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            Incidence increases with age and peaks of presentation occur in 
two age groups: at 5-7 years, the time of increased exposure to 
infectious agents coincident with beginning of school and at puberty due 
to increased pubertal growth hormone secretion which antagonizes 
insulin action. A growing number of patients are presenting between 1 
and 2 years, and about 25% of cases present after 35 years of age. 
Incidence is not affected by sex since and there is no apparent 
correlation with socioeconomic status. Seasonal distributions of newly 
diagnosed cases exist with greater frequency in autumn and winter 
months and this is more apparent in adolescent years (14). 
            There is a family history of type 1 (DM) in 10 % of cases. If a twin 
develops type 1 (DM), the life time risk to a non affected monozygotic 
twin is 60 % and for a dizygotic twin is 8 %. The risk of developing type 1 
(DM) for an individual with an affected relative is as follow: in affected 
siblings the risk is 8 %, if the mother affected is 2-3 %, 5-6 % if the father 
is affected and if both parents are affected the  risk will be 30 %(5, 15). 
1.2.2 Pathogenesis: 
              Beta cells destruction occurs in genetically susceptible people. 
At least 80% of the functional beta cells mass must be destroyed before 
overt glucose intolerance occurs. The process in most cases is immune 
mediated, probably takes months to years and may be initiated by 
external environmental factors (16). 
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 1.2.2.1 Genetics  
          Major histocompatibility complex (MHC) is important in diabetes 
both because susceptibility of type 1 (DM) appears to be linked to 
certain human leukocyte antigen (HLA) alleles and because this region 
controls immune response. Approximately 95% of Caucasians with type 
1 (DM) have either DR3 or DR4 antigens or 55 to 60% have both DR3 
and DR4. Inheritance of one of these antigens confers a 3 to 5 fold risk 
in developing type 1 DM and 10 fold risks if both are inherited.HLA DQ 
beta chain alleles primarily determine susceptibility and resistance to 
autoimmune destruction of beta cells. If aspartic acid residue occupies 
position 57 in both alleles of that chain, autoimmune diabetes ordinarily 
does not occur while full susceptibility requires absence of both alleles.  
In addition higher risk is conferred by an arginine at position 52 of the 
DQ alpha chain. It had been postulated that homozygous DR3 results in 
a primary auto immune form of type 1 (DM), and that type 1 (DM) in 
homozygous DR4 is caused by a primary environmental insult with a 
secondary autoimmune response. The risk of developing type 1 diabetes 
if one sibling is affected : Identical twins < 50%, HLA identical 1 in 5, 
HLA haploidentical 1 in 20 and HLA non identical 1 in 100 (4,17) . 
   1.2.2.2. Environmental – genetic interactions:  
          Exposure to the environmental factors may be multiple, recurrent 
and intermittent or continuous rather than a single triggering event. 
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These factors may precipitate beta cells destruction by direct damage or 
by molecular mimicry refers to the  immune response caused by similar 
protein sequences in beta cell antigens and the offending agent (e.g. 
viruses, bovine serum albumin)(18). 
       • Role of diet: 
           It has been suggested that a cell mediated response to a cow's 
milk protein, casein, may be involved in the pathogenesis of type 1 
diabetes. This suggestion was produced in an epidemiological study 
from an epidemiological study of children from 10 countries.  (19). 
        Studies in Colorado (USA) and Yorkshire (UK) have shown that 
incidence of type 1 (DM) correlates with the concentration of nitrates in 
the drinking water. The incidence is 30% higher in areas with nitrate 
concentration above 14 – 18mg/l compared with areas with 
concentration below 3.2 mg/l. 
     Dietary vitamin D supplementation also appears to correlate with risk 
of type 1 DM. In a birth cohort study of 10,000 children, those who 
regularly took vitamin D (2000 i.u daily) had a reduced incidence of type 
1 DM compared to those who regularly took less (20) . 
     • Role of viruses: 
          The viral hypothesis would explain the increased incidence of 
onset of type 1 (DM) in autumn, winter and colder climates. 
Susceptibility to diabetes after viral infection appears to be genetically 
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determined. The onset of type 1 (DM) sometimes coincides with or 
follows viral infection (such as mumps, rubella, CMV, measles, influenza, 
EBV and poliovirus).  
        Coxackie B virus specific IgM responses have been found in 39% 
of children with newly diagnosed type 1 DM, compared with only 6% of 
normal children. Also antibody titres were significantly higher in pregnant 
women whose children subsequently develope type 1 DM before 3 years 
of age, compared with pregnant women whose children did not become 
diabetic.  
         Enterovirus infections were almost two times more common in 
siblings who developed type 1 DM than in siblings who remained non 
diabetic (21).  
        In contrast to the above reports, there are data that refute the role 
of viruses in the pathogenesis of type 1 DM. There is evidence that 
viruses may protect against type 1 DM. In animal models of type 1 DM, 
inoculation with lymphocytic choriomeningitis virus at an early age 
reduced the incidence of diabetes and that raising the animal model in 
pathogen free environment leads to an increased incidence of type 1 
(DM) (22). 
1.2.2.3. Autoimmunity:  
          An ongoing search has identified several auto antigens within 
pancreatic beta cells that may play an important role in the initiation or 
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progression of autoimmune injury. It is not clear which of these auto 
antigens is involved in the initiation of the injury and which are 
secondary and released only after the injury (23). 
    • Islet antibodies: 
          • Cytoplasmic islet cell antibodies (ICAs): 
                In sections of fresh human pancreas, cytoplasmic islet cell 
antibodies are present in the serum of 60 - 90% of newly diagnosed 
patients with type 1 diabetes, compared to 0.5% of non diabetic controls. 
The antibodies generally react with all four types of islet cells, although 
in some patients antibodies are specific for beta cells. The later condition 
is less predictive of future type 1 diabetes. These antibodies disappear 
in most type 1 patient within 2-3 years after onset. The 10-15 % of 
patients in whom these antibodies persist for longer than 2-3 years 
exhibit high prevalence of thyroid autoantibodies, strong family history of 
other autoimmune disorders, female preponderance, and reduced levels 
of IgG antibodies to exogenous insulin(24). 
        •   Glutamic Acid Decarboxylase antibodies (GAD). 
                  This is the rate limiting enzyme for biosynthesis of the 
inhibitory neurotransmitter gamma amino butyric acid (GABA), and is 
expressed in several extra neural tissues including beta cells. It was 
identified in 1990 as a major auto antigen in type 1 diabetes. Antibodies 
to (GAD) are found in about 70% of patients with type 1 diabetes at the 
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time of diagnosis and may be positive 10 years before the onset of 
clinical diabetes. Measurement of the (GAD) antibodies may be the 
procedure of the choice for screening and  confirmation of the diagnosis 
of autoimmunity as the cause of diabetes. It is more reproducible, 
fluctuates less with time, is simpler to perform and is predictive of 
progression to hyperglycemia even in the absence of (ICAs) or (IAA) (25). 
        •     Insulin auto antibodies (IAAs): 
       Insulin auto-antibodies may be present in up to 50% of patients with 
new onset type 1D developing before age 5years especially those with 
DR4. Titers decline with age, in contrast to (ICAs). 
1.2.3. Prediction of type 1 diabetes mellitus: 
        1.2.3.1. Use of genetic markers: 
             Genetic markers may be helpful in assessing the risk of diabetes 
in close type 1 diabetic relatives. The risk is markedly increased, 
averaging 6% in offspring and 5% in sibling (versus 0.4% in subject with 
no family history).   
           The risk in siblings is influenced by the degree of genetic 
similarity, falling from 33% in identical twins to 12.9 to 4.5 and to 1.8%, 
respectively if the siblings share two, one or no haplotypes (26). 
      1.2.3.2. Use of immunological markers: 
             At least three islets antibodies are clinically useful (ICA), (IAA) 
and (GAD). Humans may have any combination of these antibodies, as 
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an example incidence of type 1 diabetes is not increased with (IAA) 
alone, but with the combination of (IAA) and (ICA) (27). 
   1.2.3.3. Use of metabolic markers: 
             Although glucose tolerance remains normal until close to the 
onset of hyperglycemia, the acute insulin response to several 
secretagogues (glucose, arginine, glucagons and isoproternol) 
decreases progressively during the pre clinical period. The most useful 
test is the acute insulin response to glucose (AIRg). In first degree 
relatives with type1 diabetes, an (AIRg) below the first percentile of 
normal is a strong predictor of type 1 diabetes (27). 
         Simpler test that prove useful is to measure the fasting serum 
concentration of proinsulin. In normal subject it accounts for 
approximately 15% of serum immunoreactive insulin. This proportion 
rises as beta cells function declines (28). 
1.3. Clinical Presentation and Management: 
        1.3.1. Clinical Presentation and course: 
   Most children with new onset type1 diabetes have symptoms of 
less than one month duration, but some have had mild to moderate 
symptoms for several months. 
         Most children present with the classic symptoms of polyuria, 
polydipsia, polyphagia, weight loss and lethargy. Some have 
constipation, blurring of vision and infection especially candidal skin 
- 31  - 
 
infection. Although most school children will report polyuria, in young 
children and infants this may be missed. So enquiry about bed wetting, 
nocturia and number of diapers used is important because children at 
this age are more likely to present with (DKA) with vomiting, abdominal 
pain and symptoms of systemic infection. Type1 diabetes must be 
considered in any child with clinical dehydration who continues to urinate 
regularly (29). At diagnosis most patients (approximately 75%) will not 
have DKA.  
         Type1 diabetes usually proceeds through an ordered sequence; 
prediabetes, impaired glucose tolerance, frank diabetes and  non insulin 
dependent period. After the initial presentation, most children with newly 
diagnosed type1 diabetes undergo a honeymoon period or remission 
phase. During this period the remaining functional beta cells regain the 
ability to produce insulin and so requirements of exogenous insulin 
dropped and hypoglycemia becomes a potential problem. This phase 
usually begins within 1-3 months after diagnosis and continues for 
several months, sometimes as long as 12-24months. Usually it occurs 
gradually, but as in cases of acute infection it may be abrupt .As this 
phase ends, requirements for exogenous insulin increase.  (30).       
 1.3.2. Management:  
          Normal growth in height and weight and normal timing of 
adolescent pubertal development are important goals of long term 
- 32  - 
 
management. Chronically untreated children with poorly controlled type 
1 diabetes often fail to grow normally and have delayed both skeletal 
and sexual maturation. In contrast, children receiving excessive insulin 
doses may gain weight too rapidly, have rebound hyperglycemia and 
ketosis and similar degree of growth retardation. 
           Global view to all aspects needed for glycemic control is 
warranted and integration of these parameters of treatment is essential. 
These parameters are: Insulin therapy, diet therapy, exercise education 
of the patient and his family and finally blood glucose monitoring.  
Diabetes management is difficult during adolescence and metabolic 
control often deteriorates. This is due to the hormonal changes and 
increasing maturity and independence (1, 5)           
       1.3.2.1. Insulin therapy: 
         The therapeutic objectives of insulin therapy in type1 diabetes 
include; elimination of the catabolic state and its symptoms, elimination 
of glycosuria and achievement of pre-prandial and post-prandial 
euoglycemia. 
        Effective use of insulin requires an understanding of its 
pharmacokinetics. The major variables that affect glycemic control are; 
insulin preparations, injection technique, site of injection, subcutaneous 
blood flow and size of the subcutaneous depot (31). 
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      • Insulin preparations: 
        Purified pork insulin and human insulin produced by recombinant 
DNA technology are insulin preparations most commonly used .The 
biologic effect of both is essentially identical but human insulin is less 
antigenic and has a shorter duration of action. Many reports suggest an 
increase in hypoglycemia unawareness with the use of human insulin. 
Insulin lispro is superior to the regular insulin by the fact that it corrects 
hyperglycemia more rapidly than regular insulin, very effective in use in 
intensive therapy, has fewer episodes of hypoglycemia especially 
nocturnal and it's action is not blunted by mixing with intermediate acting 
insulin in comparison to the regular one (32) . 
      Although mixing of separate supplies of short and intermediate 
acting insulin allows greater flexibility, there is little evidence that in 
routine clinical practice this leads to better glycemic control than that 
achieved by using premixed insulin. In fact, because of the variability in 
peak effect it may be more difficult to achieve excellent glycemic control 
with premixed insulin even though they are easier to use. Thus if near 
normoglycemia is the goal, it is preferable to keep basal -intermediate or 
long acting- insulin injections separate from pre-meal (regular) insulin 
and to adjust them independently. 
    The absorption of insulin and hence the duration and peak of 
activity vary among patients and from day to day by as much as 15-50 % 
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leading to unexplained fluctuation in glycemic control. This effect is 
greater with longer acting insulin and least with regular one (33).    
      • Insulin regimens  
There are two regimens used, the first is the conventional insulin therapy 
(single and two daily regimens) and the second is the intensive insulin 
therapy.  
            • Conventional insulin therapy: 
                  -  Single daily regimen: 
      It is preferred in newly diagnosed type 1 diabetics, those in honey - 
moon period and those with type 2 DM who are not controlled with 
maximum doses of drugs. The policy is to give intermediate acting 
insulin before breakfast and if post prandial hyperglycemia occurs, short 
acting insulin is added. Achieving control with a single daily injection is 
nearly impossible (1, 13). 
               - Two daily regimen: 
    If the goal is to relief from hyperglycemic symptoms with a regimen 
that is simple, then twice daily (NPH) or lente insulin will be effective in 
many patients. If excessive post-prandial rise in blood glucose is a 
concern, then regular insulin must be added. Using the later, 
approximately 2/3 of the total dose is taken before breakfast and 1/3 
before dinner. Doses usually divided as 1/3-1/2 short acting and 1/2 -2/3 
intermediate acting. This regimen is based on the concept that each of 
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the four doses is covering 1/4 of the day and results in a single peak of 
glucose absorption. This is also true for fixed insulin mixture and for the 
new preparation of lispro- Mix 25 (4).  
     Most preadolescent children need approximately 0.7 -1 u/kg/d, 
teenagers usually require 1-1.2 u/kg/d after the first few years of the 
disease. On occasions it may be as great as 2 u/kg/d while in the honey 
moon period the requirements may drop to less than 0.5 u/kg/d(4).  
      Complications of conventional therapy include: Hypoglycemia and 
hyperglycemia in the morning whether or not preceded by hypoglycemia 
(manifested clinically as Somogi and Dawn phenomenon). Also they 
include Insulin allergy which may develop with initiation of therapy 
usually within the first month or after insulin free period, (manifested as 
cutanous or systemic reactions), Insulin resistance which is present in 
the absence of obesity in type 1diabetes and recedes with good control 
and finally lipodystrophy and lipoatrophy (34). 
          • Intensive insulin therapy  
          The diabetes control and complication trial (DCCT) demonstrates 
that improved glycemic control with intensive insulin therapy in patient 
with type 1 diabetes had led to graded reduction in microvascular 
complications. The glycemic goals in the (DCCT) program were; 3.9- 6.7 
mmol/L fasting and pre-prandial and less than 3.6 mmol/L at 3AM. Hb 
A1c was to remain within 2 standard deviations of the non diabetic mean 
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level (35). Intensive insulin therapy can be accomplished in two ways: the 
first is intensified multiple subcutaneous injections, and the use of 
continuous subcutaneous insulin infusion. 
      - Multiple daily injections: 
             In general regular insulin is given before meal , and basal 
coverage is provided either by intermediate acting insulin given before 
bed time or by long acting insulin given together with regular insulin 
before the evening dose . There is a choice for premeal insulin with 
insulin lispro and inhaled insulin. The later causes very rapid rise in 
serum insulin concentrations similar to lispro and faster than the regular 
one, it is given as 1.5 units /kg 5 minutes before a meal. Food and drug 
administration approval for its use is bending (36). 
        Long acting insulin analogue, insulin glargine, gives lower fasting 
blood glucose concentrations with less nocturnal hypoglycemia as 
compared to (NPH) insulin. Since the time action of it has virtually no 
peak, this makes it the ideal basal insulin for intensive insulin therapy in 
type 1 diabetes (37). 
      - Continuous subcutaneous insulin infusion pumps (CSII): 
            It provides meticulous regulation of blood glucose and greater 
flexibility of life style especially in the timing of meals. Only fast acting 
insulin is used with this therapy, the pump is programmed to deliver 
boluses of regular insulin 30 minutes before meal and infuse insulin as a 
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constant basal rate (usually 0.5 -2 u/kg /d). The basal rate can be 
programmed for up to 4 different basal rates in a 24hr period. The lower 
rate to supply low nocturnal requirements and the higher rate to cope 
with the early morning hypoglycemia. 
      Advantages of meticulous control are:  1- insulin absorption is less 
variable from day to day, and therefore blood glucose  profiles are  more  
predictable. 2- near normal levels of amino acids and lipid profile are 
achieved.  3- Normal plasma glucagon levels and normal responses of 
counter regulatory hormones.4-improvement of neuropathic components 
of the diabetic syndrome, reversal of microalbuminuria and slowing the 
progression of early retinopathy (38). 
        Disadvantages of meticulous control: 1- Retinopathy acceleration  
2- Severe neuroglucopenia and hypoglycemia unawareness 3-obesity 
(39)
. 
           1.3.2.2. Diet therapy:  
       For many years the (ADA) recommended standard diet in the 
treatment of diabetes: Approximately 30% of dietary energy should be 
derived from fat, 20 % from protein and 55 % from carbohydrates and 
high fiber food with only modest amount of sucrose and refined sugars. 
No particular food should be considered forbidden, and allowing diabetic 
patients to consume up to 10% of their caloric intake as added sugars or 
sweets doesn't appear to negatively impact metabolic control. The timing 
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of the meals must be carefully matched with that of insulin injections if 
normoglycemia is to be achieved (40). 
   1.3.2.3. Exercise: 
         Physical fitness and regular exercise are important for all patients 
with type 1 diabetes because insulin requirement may be lower and 
metabolic control improves (41). 
    1.3.2.4. Monitoring glycemic control: 
           Two ways are available for monitoring glycemic control; 
measuring blood glucose concentration and testing urine for glucose and 
ketones. 
         • Mean blood glucose concentration: 
        The (ADA)  recommends that patients with type 1D monitor their 
blood glucose four times daily, before each major meal and at bed 
time, more frequent testing ( up to seven times ), may be indicated if 
the child is unwell, partaking in heavy activities or feel hypoglycemic. 
The mean of these values is termed the mean blood glucose 
concentration which is one of the useful measurements for defining 
glycemic control (42). 
     The fasting blood glucose concentration is often used to monitor 
progress since it correlates well with HbA1c value; although some 
authors have argued that non fasting blood glucose is a better marker of 
glycemic control than fasting values. The child should aim at a pre-
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breakfast blood glucose of 6-8mmol/L, ( some recommend a lower range 
to be 4mmol/L ), pre-lunch and pre-evening meal values of 4-8mmol/L, 
pre-bed time level of 7-10 mmol/L and < 10 mmol/L two hours after 
meal. In children less than five years of age acceptance of slightly higher 
glucose concentrations may be necessary to avoid hypoglycemia which 
may be a consequence of variable feeding patterns (43). 
        • Glycosylated HbA1c:  
     Glucose can attach to many proteins via a non-enzymatic process. 
The average amount of HbA1c changes in a dynamic way and reflects 
the mean blood glucose concentration over the previous 6-8 weeks. 
Values are influenced by red blood cells (RBCs) survival, falsely high 
values can be obtained when RBCs turnover is slow and vice versa. It is 
recommended to be measured every 3-6 month. The (DCCT) aims for 
HbA1c value of 7%; interpretation for its values is as follows (44, 45, and 46), 
5 - 5.9 % → within non-diabetic reference range with a possibility of 
hypoglycemia, 6 - 6.9 % → ideal glycemic control, 7 -7.9 % → good 
glycemic control in the absence of complications, 8 - 8.9 % → 
associated with increased risk of microvascular complications, 9 -10.9 % 
→ compliance likely to be a problem. Associated with high risk of 
microvascular complications, > 11%   → poor compliance. 
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        • Fructoseamine:  
          Many proteins other than hemoglobin can also undergo non-
enzymatic glycation leading to the formation of advanced glycosylation; 
Fructoseamine is one of them. The disadvantages of fructoseamine are 
that its turnover is more rapid than the hemoglobin (28 versus 120 days) 
and its value must be adjusted to serum albumin (47). 
           •urine testing for glucose and ketones:  
           It has a potential errors that limits it's accuracy as a reflection of 
glycemic control.  Urine test may be negative in patient with normal, low 
or high blood glucose .For these reasons blood glucose is 
recommended for all diabetic patients aiming for strict glycemic control. 
    Testing for ketonuria is less subject to error because any positive 
value suggests the presence of ketonemia (48). 
1.4. Complications and Prevention: 
             1.4.1. Potential Mechanism in the Pathogenesis of 
Complications: 
          The various diabetic complications don't necessarily have the 
same pathologic mechanism. Three possible mechanisms have been 
implicated in tissue changes, these include: 1- over glycation of proteins 
2- increase in polyol pathway and 3- hemodynamic abnormality.  
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1.4.1.1. Glycation of proteins:                     
          All proteins in the body can undergo glycation if exposed to 
elevated glucose .Non-enzymaticaly glycated proteins slowly form 
fluorescents cross-linked proteins called advanced glycation end 
products or Ages. Receptors for these proteins are expressed on 
endothelial cells, fibroblast, mesangial cells and macrophages. 
Functional consequences of AGEs include cataract, limited joint mobility, 
neuropathy and hyperlipidemia with its sequences (macro vascular 
complications) (49). 
         1.4.1.2. Polyol pathway:  
          In this pathway glucose is reduced to sorbitol by the enzyme 
Aldose reductase which is present in the retina, kidney papillae, lens, 
schwan cells and aorta. It has been implicated in the pathogenesis of 
cataract, retinopathy, nephropathy and aortic disease (50).  
1.4.2. Complications: 
            Acute complications include hypoglycemia and diabetic 
ketoacidosis. Long term complications include; retinopathy, nephropathy 
and neuropathy termed microvascular complications (develop in puberty 
and early adulthood) and atherosclerosis and its sequel are termed 
macrovascular complications (affect mainly older adults).  Other 
complications include cardiomyopathy, dermopathy, joint dysfunction, 
growth disturbances (growth failure and poor or excessive weight gain), 
- 42  - 
 
delayed puberty and autoimmune diseases. The risk of complications 
may be increased by genetic factors, poor glycemic control, smoking 
and duration of diabetes where complications increased with increased 
duration (3, 5, 51). 
1.4. 3. Prevention of type 1 diabetes mellitus: 
            The prevention of autoimmune diabetes is a realistic possibility. 
The autoimmune process of type 1 diabetes begins years before beta 
cell destruction becomes complete, there-by intervention is possible. 
Potential prophylactic agents are: 
 • Insulin: Oral insulin is reported to reduce the severity of lymphocytic 
infiltration in the pancreatic islets by acting as immunomodulator. 
Aggressive insulin treatment of new onset type 1 diabetes in humans 
increases the frequency and duration of insulin free remissions (52). 
• Immunomodulation: 
            A- Azathioprine: is an immunosuppressive drug that inhibits or 
prevents T-cell responses to antigens. Insulin could be discontinued with 
its use in a number of patients but for no longer than one year (53). 
           B- Cyclosporine: A series of large scale trials in recently 
diagnosed type 1 diabetes in Canada and France revealed that 
remission were twice as common in the cyclosporine treated patients 
compared with placebo. Although the remission lasted longer, almost all 
patients required insulin again within 3 years. 
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         C- Nicotinamide : A 20 nation international clinical trial ;the 
European Nicotinamide Diabetes Intervention Trial (ENDIT) is underway 
and the initial results suggest that the onset of type 1 diabetes can be 
delayed by nicotinamide if it is started early enough (54) .  
• Whole or partial pancreatic transplants have been successful in 
treatment with type 1 diabetes, but they require life long 
immunosuppressant.  
         Further treatment is the use of specific immune therapy targeted at 
the initiation of autoimmune process. In view of the success of 
immunomodulation with bacillus Chalmette-Guerin (BCG) in mice, BCG 
has been given to 17 newly diagnosed patients with type 1diabetes, 
11(65%) went into remission for up to 10 months. This success rate was 
significantly better than in control patients, and there were no side 
effects (55). 
1.5. Lipids of physiologic significance: 
     1.5.1   Definition: 
            Lipids are a heterogonous group of organic compounds that are 
actually or potentially esters of fatty acids. They have the common 
properties of being relatively insoluble in water and soluble in non-polar 
compounds such as ether, Chloroform and benzene (56). 
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1.5.2 Biochemical importance: 
          Lipids are important dietary constituents because they are source 
of high energy value, fat soluble vitamins and essential fatty acids. They 
play many roles in the body eg in adipose tissue serves as storage form 
of energy and serve as thermal insulator in subcutaneous tissues and 
around certain organs. On the other hand, non-polar lipids act as 
electrical insulators allowing rapid propagation of depolarization waves 
along myelinated nerves and finally lipoproteins enter in the structure of 
cell membranes and mitochondria (57) . 
 1.5.3. Classification: 
      1.5.3.1 Simple lipids   :  
         Simple lipids are esters of fatty acids with various alcohols, divided 
into: 
• Fats (Acylglycerol): esters of one, two or three fatty acids with glycerol,    
named as mono, di, and triacylglycerol respectively .Triacylglycerol in 
the liquid state at room temperature is known as oil, while that in the 
solid state is known as fat. 
 • Waxes: are esters of fatty acids with higher molecular weight 
monohydric   alcohols. 
        1.5.3.2. Complex lipids:  
       Complex lipids are esters of fatty acids containing groups in addition 
to an alcohol and a fatty acid:   
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• Phospholipids: containing phosphoric acid residue such as glycerol in 
glycerophospholipid and sphingosine in sphingophospholipids, are the 
main lipid constituents of membranes. 
• Glycolipids (glcophosphlipids): lipids containing Sphingosine, fatty 
acids and carbohydrate –important in nerve tissues and cell membrane-. 
• Other complex lipids: such as sulpholipids (containing sulphar), Amino- 
lipids (containing amino acids) and lipoproteins (containing proteins) (58). 
         1.5.3.3. Precursors and derived lipids:  
      These include fatty acids, glycerol, steroids and fatty aldehydes. 
Others include alcohol, lipid soluble vitamins, ketonbodies and 
hormones. 
           • Neutral lipids: Are those which carry no charges and include 
neutral fats (acylglcerols), Cholesterol and cholesteryl esters (59). 
              plasma lipids in humans are triglyceride(TG) 45%, total 
phospholipids 35% , total cholesterol (TC) 15% and free fatty acids < 
5%.  
        • Cholesterol:  
              Cholesterol is an alcohol that occurs in the circulation in two 
forms; the free cholesterol accounting for about 30% and it is the form 
that exchange readily between different lipoproteins and cell 
membranes. The other form is combined with a long chain FA as 
cholesteryl ester accounting for the remainder 70% (storage form of 
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cholesterol). It is an amphipathic lipid (hydrophobic-hydrophilic) and as 
such is an essential structural component of the outer layer of plasma 
lipoproteins and of membranes in everybody cell especially adrenal 
cortex, liver, kidney, brain and nervous tissues. It is the precursor of all 
other steroids in the body such as corticosteroids, sex hormones, bile 
acids and vitamin D (60).  
      A little more than half the cholesterol of the body arises by synthesis 
(about 700 mg /day). The liver account of about 10% of total synthesis, 
the intestine for about another 10%, other organs are the adrenal cortex 
and reproductive tissues. All tissues containing nucleated cells are 
capable of synthesizing cholesterol from acetyl coA derived from 
glucose oxidation (61).  It is mainly a product of animal origin e.g. meet, 
liver, butter fat, beef fat and brain, or in it's counterparts in plants named 
phytosterl e.g. palm oils (56). 
       •Triglycerides: 
           Triglycerides are quantitatively the most significant lipids. They 
constitute the majority of lipids in the body. They are important as a 
major constituent of lipoproteins and as the storage form of lipids in 
adipose tissues. 
        Triglyceride is the major portion (98-99%) of the animal lipids, the 
remainder being cholesterol and other lipids. From animal sources e.g. 
cod liver oil, butter lard, shark liver oils, it tends to solify at room 
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temperature, while those from plant source e.g. cotton seed, sesame, 
olive and linseed oils remained liquid even at refrigerator temperature. In 
the body (TG) are synthesized in most tissues from activated fatty acids 
and phosphorylated C3 product of glucose catabolism (62). 
      •Fatty acids: 
       Non essential fatty acids can be synthesized in the body from 
acetyl CoA derived from glucose oxidation or derived from external 
sources such as vegetable oils. 
     • Lipoproteins:     
     Lipoproteins are a heterogeneous group of lipid-protein complexes 
synthesized mainly in the intestine and liver and serve a wide variety of 
functions in the blood; transporting lipids from tissues to tissues and 
participating in lipid metabolism.  In addition to free fatty acids four major 
groups of lipoproteins have been identified in normal fasting human; very 
low density lipoproteins (VLDL), low density lipoprotein (LDL), 
intermediate density lipoprotein (IDL), high density lipoprotein (HDL) and 
a fifth type named chylomicron in the post absorptive period (63). 
1- VLDL (pre-B-lipoprotein): Most of it is derived from the liver for the 
export of triglycerol to extra hepatic tissues .In the plasma it is converted 
to IDL and LDL. 
2- LDL (B-lipoprotein): Represents the final stage of VLDL, is the major 
transporter of cholesterol in the plasma (64). 
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3- HDL (α-lipoprotein): Involved in (VLDL) and chylomicron metabolism 
and cholesterol transport from tissues to the liver a process known as 
reverse cholesterol transport.  
      Triglyceride is the predominant lipid in chylomicron and (VLDL), 
Phospholipids are the predominant lipid in HDL and Cholesterol is the 
predominant lipid in (LDL). The purified protein component of a 
lipoprotein particle is called apolipoprotein; each type of lipoprotein has a 
characteristic apolipoprotein composition eg Apo A1 is prominent in 
(HDL) (2, 4). 
1.5.6 Lipid metabolism: 
      In general the incorporation of exogenous lipids occurs in three 
phases: 1- digestion 2- absorption 3- transport. 
• The digestive phase: In this phase; emulsification a process 
by which lipid granules are broken up, started mechanically 
in the mouth and completed in the small intestine by the 
action of bile secreted from the gallbladder. Bile is composed 
of lethicin and cholesterol and conjugated bile acids, the 
highly amphipathic properties of the latter breaks up lipids 
into smaller micelle units rendering them more vulnerable to 
the action of digestive enzymes. Three hydrolytic enzymes 
are produced by the pancreas and secreted into the 
duodenum. These are the  pancreatic lipase which acts on 
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TG to yield ( FAA), forming monoglyceride ,diglyceride and 
glycerol, cholesterol esterases which cleaves the ester 
linkages to release (FFA) and free cholesterol and the 
phospholipase A which hydrolysis the exogenous 
phospholipids .  
• The absorptive phase:  In this phase the various micelle 
components diffuse across the brush border into the mucosal 
cells where the lipid content of the micelles are absorbed 
while the bile salts passed down to the ileum. Inside the cell, 
monoglyceride and (FA) are reesterified to (TG) and 
cholesterol esters   . 
• Transport phase:  At this stage the nature of the lipid 
transportation mechanism depends on the lipid molecules 
being transported. The (TG) and other fat soluble molecules 
eg cholesterol and phospholipids are incorporated into 
chylomicron and released into the lymph of the thoracic duct, 
in order to enter the circulation eventually. Short and medium 
chains (TG) as well as small amount of long chain (FA) are 
transported in the portal vein bound to albumin. Bile acids are 
transported back to the liver through the enterohepatic 
circulation (65). 
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           Fat absorbed from diet and lipid synthesized by the liver and 
adipose tissues must be transported between the various tissues for 
utilization and storage. Since lipids are insoluble in water, the problem 
arises of how to transport them in the blood .This is solved by 
associating non-polar lipids (TG and cholesterol esters) with amphipathic 
lipids (phospholipids and cholesterol) and lipoproteins to make water 
miscible lipoproteins (57). 
      Chylomicrons are the largest of the lipoprotein fractions .In order to 
pass through the endothelial cells of the capillaries, need to be 
hydrolyzed first .they interact with (HDL) and activate lipoprotein lipase 
which catalyzes the hydrolysis of triglycerides. Triglyceride is provided to 
tissues as  monoglycerides, glycerol and free fatty acids; the later 
quickly  bind to albumin and taken up by the cells to be used for storage 
as (TG) and for energy production .Having lost most of it's triglyceride 
contents ,the chylomicrons interact with (HDL) again to became 
chylomicron reminant  which contains  primarily cholesterol esters. 
Receptors in the liver facilitate endocytosis of the reminant and its 
hepatic degradation to release (TGs) and yield (VLDL) which again is 
hydrolyzed to produce (IDL) and (LDL). LDL is rich in cholesterol and 
has receptors on the membranes of hepatocytes and peripheral tissues 
by which it is engulfed leading to deposition of cholesterol in the 
cytoplasm (57, 66). 
- 51  - 
 
1.5.6.1 .Regulation of lipid metabolism: 
        • Hormonal regulation: 
          The rate of release of (FFA) from adipose tissues is affected by 
many hormones that influence either the rate of estrificaton or the rate of 
lipolysis. Several hormones promote lipolysis and accelerate the release 
of (FFA) from adipose tissues. These include epinephrine, 
norepinephrine, glucagons adrenocorticotrophic hormone, thyroid 
stimulating hormone, growth hormone and vasopressin. 
   Insulin inhibits release of (FFA) from adipose tissue leading to fall in 
its concentration in the plasma. Hence in cases of insulin deficiency 
sustained increase in plasma (FFA) levels occur. Insulin exerts its action 
in two ways: First insulin enhances lipogenesis and synthesis of 
acylglycerol by adipose tissue by several ways. And secondly, the 
principal action of insulin in adipose tissue is to inhibit the activity of the 
hormone sensitive lipase, which enhances FFAs release. Plasma (FFAs) 
concentrations are more responsive than glucose to small changes in 
circulating insulin levels due to greater insulin sensitivity of adipocytes 
than most other insulin responsive tissues (67) . 
 • Dietary regulation: 
       When the amount of dietary cholesterol is reduced, cholesterol 
synthesis increases to satisfy the needs of other tissues and organs .In 
contrast, when the dietary cholesterol increases synthesis is almost 
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totally suppressed. This is achieved through the feed back inhibition of 
the activity of 3-hydroxy-3 methylgluteryl-CoA reductase (HMG CoA) 
which governs the rate limiting reaction in the pathway of cholesterol 
biosynthesis (58, 64). 
 
1.6. Clinical application: 
       Abnormalities of lipoprotein metabolism occur either at the sites of 
production or utilization of lipoproteins causing various hypo (decreased) 
or hyperlipidemias (increased). The most common cause of lipid 
abnormality is (DM). Most other pathologic conditions affecting lipid 
transport are primarily due to inherited defects (56). 
  • Hyperlipidemia: 
          Most of the hypercholesterolemia and hypertriglyceridemia in 
children are secondary to exogenous or underlying clinical factors (68): 
• Metabolic conditions; (DM), low (HDL), high 9LDL). 
• Life style; smoking, physical inactivity, severe obesity. 
• Hypertension/other underlying conditions: renal disease (renal 
failure, transplant, nephritic syndrome), Liver disease (biliary tract 
disease, cirrhosis and acute viral hepatitis). 
• Endocrinopathy: hypothyroidism, Cushing syndrome. 
• Drugs: cyclosporine A, thiazide and contraceptive pills. 
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• Storage diseases; Tay-sach, glycogen storage disease. 
       These conditions are relatively frequent in children and adolescents 
and need to be searched for, because they can be influenced by 
treatment of the underlying disorder (69,7o). 
  
 
1.6.1. Screening of lipids in children: 
      1.6.1.1. Why to screen? 
              Interest in the study of plasma lipids has been at it's height in 
the last one to two decades because of the close association between 
hyperlipidemia and the development of atherosclerosis in children. This 
fact poses the question of diagnosis and treatment of risk factors. There 
was a controversy whether cholesterol should be searched for by 
universal or by selective screening or by no screening at all (71, 72) . 
       In recent years cholesterol has been the third nationally 
recommended health screening test in United State population and is 
highly recommended by the national Heart, Lung and Blood institute for 
both adult and children (73). 
       Lipid levels show differences in different populations and are 
shown to be affected by age, sex, height, life style, infection and 
genetics (74, 75, 76). In addition levels may be affected by the type of food 
ingested (77). 
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      Several screening studies have been reported in non-diabetic 
children of different ages and from different populations. In a study by 
Knuiman and his group in 1983, plasma cholesterol levels in children 
aged 8-9 yrs from different countries were compared. The results 
showed variations in the cholesterol levels; the highest level was in 
children from Finland while the lowest was in children from Ghana (78). In 
a similar study on 13 yrs old children in which 15 countries were 
compared, the highest cholesterol level was in children from Finland and 
the lowest was in children from Nigeria (79). 
       Mohsen A.F.Elhazimi in the year (2001), studied the prevalence of 
plasma lipid abnormalities in Saudi children aged 1-15 yrs and found 
that the prevalence of lipid abnormality varied in the different age group 
where the higher mean (TC) was in the 3-4 yrs olds and a significant 
decrease occurred with age, with the lowest mean in those aged 14-
15yrs, while the highest level of (TG) was in the 2-3 yrs old and the 
lowest in those aged 8-11 yrs (these changes in lipid may result from 
sexual maturation and related hormonal levels). Cholesterol levels were 
found to be lower than those reported in Finland, New Zealand and Italy 
and similar to the Philippine population and higher than the population in 
some of the African countries (79).  Over 9% of all Saudi children and over 
10% of those between 3-14 yrs of age fall in the high risk group for 
(CHD) development when cholesterol levels are used (80). 
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     As part of an epidemiological study on the cardiovascular risk 
factors among children and adolescents in Navara; lipids and 
lipoproteins were analyzed in 5829 children aged 4-17 yrs of both sex. 
Results showed prevalence of hypercholesterolemia of about 21.07 %, 
the lipid risk of LDL/HDL is very high 15-70 % and male adolescents turn 
out to be the group with the highest risk (81). 
     Hyperlipidemia and atherosclerosis group in Canada analyzed the 
relationship between Apo E phenotype and plasma lipid levels in 45 
population samples from 17 different countries (1992). Results indicate a 
consistent relationship between plasma (TG) level and Apo E phenotype 
among different populations and that (TG) concentrations were 
significantly higher in Apo E 2 than Apo E3 and that (HDL) is significantly 
lower in Apo E4 than Apo E3(82) . 
1.6.1.2. Whom to be screened? 
     Measurement of total cholesterol or lipid profile should be 
performed only under certain defined circumstances .The American 
Academy of Pediatrics (AAP), The American Heart Association (AHA) 
and National Cholesterol Program (NCEP) don't recommend routine 
total cholesterol screening in children. 
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 Indications of cholesterol testing together with the recommended tests 
are as follows (83, 84, and 85):  
• In children as general (above the age of two years): 
           -Parent with (TC) of 240 mg /dl or more → measure (TC) 
           -Family history of premature coronary heart disease (CHD) →   
            measure fasting lipid profile 
           -Family history of dyslipidemia (abnormal lipid profile) → measure 
            fasting lipid profile 
           -Pediatric medical condition that predisposes patients to CHD of  
                      dyslipidemia → measure fasting lipid profile.  
          - Family with unknown history (include situations in which parental 
                      TC values are unknown) → measure (TC).  
• In diabetic children: 
         Type 1:  
           -  More than 12 yrs of age (assumed to be pubertal): screening 
should be done at diagnosis but after glycemic control is achieved and 
should be repeated after 5 yrs if the initial screen is normal. 
         - In those < 12 yrs of age (generally per pubertal): in the absence 
of parental history of dyslipidemia or early (CHD), there is no clear 
indication for screening. 
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         Type 2: 
             - Screen at diagnosis regardless of age but after glycemic 
control is achieved, if normal lipid values are obtained, screening 
should be repeated every 2 yrs (84, 85). 
         Although universal screening would make it possible to identify all 
those with high cholesterol levels, it has significant draw backs. The 
panel decides not to recommend universal screening for the following 
reasons: 1- quite a few children with high cholesterol levels will not have 
high enough levels as adults to qualify for individualized treatment. 2- 
Many young people will be labeled as patients with a disease, causing 
unjustified anxiety for them and their families and  3- There is insufficient 
evidence concerning the long term safety and efficacy of drug therapy in 
childhood to reduce (CHD) morbidity and mortality in adulthood(85) . 
  1.6.2. Analytical procedures  
     In the past lipid profile was consisted of (TC), (TG) and the serum 
appearance after standing in the refrigerator for several hours. Now 
sophisticated methods are advanced to quantities the various lipoprotein 
fractions .When TC, TG, HDL.C, and LDL.C are measured in a single 
sample the test is termed lipid profile. Abnormalities in (TC) including 
(HDL-C) and (LDL-C) with or without abnormal (TG) level is termed 
dyslipidemia (61).   
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     Children should be in their regular diet for 4-6 weeks before 
testing .Recent changes in the diet or severe illness (eg hospitalization 
within the last 4-8 weeks) is a contraindication for testing because 
significant stress can lead to transient decrease in lipid levels or 
transient lipid abnormalities( borderline or elevated levels) as in 
hypertriglyceridemia following (DKA). Lipoproteins are acute phase 
reactants and their concentration declines within 24 hours of acute 
severe illness. Measurement of (TC) and (HDL.C) don't need to be 
performed in the fasting state. Unlike (TG) in  lipid profile which must 
always follow an over night fast for at least 8 hours and preferably 12-14 
hours. LDL.C can either be measured directly and so doesn't require a 
fasting specimen or calculated as part of the lipid profile when (TG)  are 
less than 400 mg /dl using a Friedewald equation. LDL.C = TC– (HDL.C 
+TG/5). TG/5 represents the VLDL.C (86). 
       Cholesterol level is influenced by 1- menstruation; level increases 
before it, peaks at and then declines 2- haemolysis; dilutional effect may 
occur with gross haemolysis (87).  Individualized specialized tests that 
can be ordered if unexplained (CHD) is present in the family are the 
apolipoproteins (2, 4).  
    The National cholesterol education program (NCEP) determined the 
different plasma lipid levels in children in mg/dl as shown in the table 
below (85, 88). 
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Table (1) 
Children < 20 
years 
Desirable level  Borderline 
level 
Elevated level  
TC <170 170—199 > 200  
LDL.C <110 110---129 > 130  
HDL.C >45    35---45 <35 
*TG <125 - > 125 
 
  * Not established by NCEP, 125 mg /dl approximates the mean 95th 
percentile for (TG) in boys and girls during childhood and adolescence. 
   * Optimal lipid levels for diabetics are in accord with those of the Third 
Adult Treatment Panel and (AHA):   LDL < 100mg/dl,   HDL > 35mg/dl   
and TG < 150 mg/dl (84).  
1.7. DIABETES AND LIPIDS: 
      Under normal conditions the reactions of the metabolism of various 
nutrients proceed in a manner which would allow the maintenance of 
constant levels of various intermediates. It is only when a certain 
metabolite is accumulated in an unusual quantity the state of equilibrium 
is shifted. One example of such a situation is (DM). 
        In diabetes utilization of glucose is decreased and as a result 
most of the energy is obtained from oxidation of (FA) to acetyl CoA 
through the citric acid cycle (CAC). For efficient glucose utilization an 
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adequate amount of oxaloacetate is required. Under normal conditions 
this is met by its production from pyruvic acid, aspartic acid and glutamic 
acid.  In (DM) the formation of oxaloacetate is greatly reduced due to 
lower rate of glycolysis so oxaloacetate is derived mainly from amino 
acids thereby depleting the tissue proteins. Further more the function of 
the (CAC) is diminished to a marked extent as the higher  concentration 
of long chain fatty acyl coA  inhibits the first enzyme in the (CAC) and 
leads to a small utilization of acetyl coA and ultimately generates less of 
energy which would be one of the causes of weakness in diabetic 
patients. Fatty acyl CoA also inhibits acetyl CoA carboxylase (the first 
enzyme in FA synthesis). This is the probable explanation of depressed 
lipogenesis and increased levels of (FFA) in the plasma (2). 
 
1.7.1. Lipid Abnormalities in Diabetes:  
     Hypertriglyceridemia is common in diabetes both as a transient 
component of poor metabolic control and as a persistent finding in some 
relatively well controlled patients. In the later situation a genetic form of 
hyperlipidemia may coexist with diabetes. Two mechanisms may be 
operative for the hypertriglyceridemia: The decreased level of lipoprotein 
produces a defect in lipolysis of TG and the increased level of (FFAs) 
provides substrate for over production of hepatic (VLDL) and (TG). 
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Insulin therapy reverses both of these defects and restores TG levels to 
normal.  
         In type 1 (DM) elevated levels of (LDL.C) result from several 
factors: Insulin deficiency may reduce the activity of LDL receptors, 
consumption of excess saturated (FAs) and cholesterol can suppress 
the activity of (LDL) receptors and accentuates the rise in (LDL) levels 
and the last that glycation and oxidation of LDL may reduce the affinity 
of LDL to its receptors and thereby lower its clearance rate. The 
incidence of elevated LDL .C in diabetic patient is not as high as that of 
hypertriglyceridemia (89). 
 
 
 
 
1.7.2. Shared Complications of lipids and diabetes: 
     1.7.2.1. Atherosclerosis:  
Atherosclerosis is a disorder of the arterial wall characterized 
by the accumulation of cholesterol and it's esters (referred to as fatty 
streaks) in cells derived from monocots macrophage line in the sub-
endothelium of large muscular arteries .This layer is then covered by 
fibromuscular cap forming a fibrous plaque named atherosclerotic 
plaque which narrows the blood vessel and serve as a site for 
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thrombus formation by promoting platelet aggregation. These changes 
were found in children as young as 3 yrs. The condition is clinically 
manifested as stroke, myocardial infarction and peripheral arterial 
disease. (90). 
          Systemic epidemiological and pathological studies documented 
the childhood origin of atherosclerosis and its progress slowly into 
adulthood at which time it leads frequently to coronary heart disease, 
one of the major causes of death (79, 91). Identified risk factors contributing 
to the early onset of (CHD) in children and adolescents include (92): 
• Metabolic:   high LDL, HDL < 35 mg/dl and DM. 
• Family history of premature (CHD) or peripheral vascular Disease 
                   (before age 55 yrs). 
 
 
• Life style:   smoking, physical inactivity and obesity especially  
                   abdominal (>95th Percentile weight for height on the national 
                   Center for health Statistics)   
• Hypertension.   
      Diabetes is a major risk factor contributing to the development 
of atherosclerosis and   considered a  coronary  heart  disease  
equivalent (83). 
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Oxidation of elevated LDL levels is thought to be atherogenic. It's 
uptake by monocytes /macrophage cells leads to the formation of 
the foam cells the precursor of the atherosclerotic lesion. AGEs play 
a role in lipoprotein oxidation and auto antibodies against glycated 
LDL. Low levels of HDL in diabetic patient may result also from 
glycation which accelerate its turnover or accelerate TG formation. 
HDL protects against atherosclerosis by two mechanisms; first by 
reversal of cholesterol transport and second by inhibition of LDL 
oxidation. Increased platelet aggregation may contribute to diabetes 
atherogenesis possibly as a result of elevated levels of Von 
Willebrand factor and diminished level of prostacyclin (an inhibitor of 
platelet aggregation) (2) . 
         To determine whether these risk factors are also associated with 
atherosclerosis many studies were done in both diabetic and non-
diabetic patients. 
          A longitudinal cohort over 15 yrs was identified from a 
community study of the natural course of atherosclerosis including 
1169 individuals aged 5-14 yrs. Results of lipoprotein variables in 
childhood were associated with that in adulthood; more strongly for TC 
and LDL.C than for TG and HDL.C. Adverse levels of LDL.C in 
childhood persist overtime, progress to adult dyslipidemia and relate to 
obesity and hypertension as well. This tracking of dyslipidemia 
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suggests that most but not all of children with dyslipidemia will have it 
as adults, this is in part related to the dramatic decrease in total 
cholesterol seen as children progress through puberty (93). 
            In the year 1994 arteries and tissues from approximately 3000 
autopsied persons aged 15-34 yrs were examined in the Bogalusa Heart 
study. The extent of both fatty streaks and fibrous plaques in the right 
coronary artery and abdominal aorta associated positively with increase 
in (TC), (LDL), hypertension, impaired glucose tolerance, smoking and 
obesity.  Age, sex and race were independent factors (91). 
           The pathological determinants of atherosclerosis in youth (PDAY) 
study (1999) reported that LDL.C, severe obesity and elevated HbA1c 
levels were significantly correlated with the postmortem diagnosis of 
coronary atherosclerosis (94). 
          In the Muscatine study increased body mass index (BMI), blood 
pressure (BP) and low (HDL.C) were correlated with the early 
development of coronary calcification (considered a marker of 
atherosclerosis). The prevalence of coronary calcium in adolescent with 
familial hypercholesterolemia is 25% and the presence of calcium is 
more likely with the highest (BMI) (95, 96). 
       Few data are available on which to base goal levels for two major 
risk factors namely (BP) and lipid/ lipoproteins. To determine at which 
levels of (LDL) , (HDL) ,(TG) and (BP) the relative risks of type 1(DM) 
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complications  increased significantly; Orchard TJ   and his colleges in 
the epidemiology of diabetes complication study followed up 589  
diabetic patients over 10 yrs for incidence of mortality, (CHD) and 
microvascular complications. The suggestive goal levels were; LDL.C< 
100 mg /dl, HDL>45 mg/dl, TG < 150 mg /dl, systolic BP < 120mmHg 
and diastolic one < 80 mmHg and complications was found to be 
associated with levels above these.  Age, sex and glycemic control had 
little influence on these goals .The conclusion was that vigorous control 
of BP and lipid abnormalities is needed (79). 
   1.4.2.2. Retinopathy and nephropathy. 
          The association of dyslipidemia with microvascular complications 
has been less investigated. It may cause or exacerbate diabetic 
retinopathy and nephropathy by alteration of the coagulation fibrinolytic 
system, changes in membrane permeability, damage to endothelial cells 
and increased atherosclerosis .Hyperlipidemia is associated with faster 
decline in glomerular filtration rate and progression of albuminuria and 
nephropathy. Recent evidence also suggests a role of lipoprotein (a) in 
progression of retinopathy and nephropathy (98). 
        There is some evidence to implicate serum lipids in exudative 
maculopathy. Cross sectional studies suggest that higher serum lipids 
are found in patients with macular exudates. Lipid lowering therapy may 
significantly benefit diabetic retinopathy and nephropathy. However, 
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most of the data are based on short term studies and need to be 
ascertained (98). 
 
1.8. Management of dyslipidemia: 
                Prevention of (CHD) is the goal of lipid abnormalities treatment. 
The risk increases with increasing plasma cholesterol and (LDL). High 
(TG) although not an independent risk factor for (CHD), is generally 
accompanied by low (HDL) which may predispose to it. Lowering LDL and 
increasing HDL are thus goals in prevention. (86). 
        Patients with borderline or elevated levels of lipids should be 
subjected either to dietary or both dietary and pharmacological treatment 
according to the (NCEP) recommendations (85). 
• LDL.C and TC:  
           Acceptable levels → provide education on eating pattern 
recommended and provide (CHD) risk factors advice including 
measurement of (BP) regularly, anti-tobacco counseling, encouragement 
of physical activity and management of obesity. Repeat lipoprotein 
analysis in 5 yrs. 
       Borderline levels → provide risk factor advice, initiate step one 
diet therapy and other risk factors intervention. Re-evaluate the patient 
status in one year duration. 
With lipid values greater than the optimal levels: 
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- Blood glucose control should be maximized and dietary 
counseling should be provided. 
       - Follow up of fasting lipid profiles should be performed at 3 month 
and then at 6 month to determine the effect of the above measures. If  
   treatment goals are achieved lipid profile should be repeated yearly,      
   but if failed further intervention is warranted based on  (LDL) levels       
   shown below: 
      -Borderline levels → maximize non pharmacologic treatment. 
         - LDL level 130--159 mg/dl→ consider medications, basing the 
treatment decision on the child (CHD) risk factors.                                                 
         - LDL levels > 160 mg/dl and TC > 200 mg/dl → start  medications. 
B.Triglycerides:   
           Elevated levels are not directly managed with medications. If > 
150 mg /dl → maximize blood glucose control and achieve desirable 
weight. If > 1000 mg /dl (increased risk of pancreatitis is present) → start 
medications. Serum LDL levels can be lowered by reducing saturated fat 
and cholesterol intake and reducing weight. Serum TG can be lowered 
by substitution of starch for sugar and weight reduction while Serum 
HDL can be raised by decreasing cigarette smoking, increasing physical 
activity and good control of diabetes (99). 
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1.8.1. Diet therapy: 
       Dietary modifications are the bases of treatment in children. The 
NCEP recommends management of lipid disorders as shown in table 
2(85, 99).  
  Table (2):  
Nutrient                                               recommended intake  
                                              Step one                               step two                                                            
Total fat                          no more than 30% of  
                                       total calories  
 
saturated FA                   <10 % of total calories                      <7%    
 
polyunsaturated FA          up to 10%                                         same                   
 
monounsaturated FA            remaining fat calories                  same                  
 
cholesterol                             > 300 mg/day                             >200                  
 
carbohydrates                      55% of total calories                      same  
 
proteins                              15-20 % of total calories                same                  
calories                               to promote normal growth              same   
                                          and development.                                               
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          The international society of pediatric and adolescent diabetes 
(ISPAD) recommendations for dietary fat intake in type 1 diabetics is 
same as those shown above (100). The (ADA) recommends an 
individualized diet with intake similar to other children, as comparable to 
(ISPAD) recommendations (101). 
             In patients with severe hypercholesterolemia dietary cholesterol 
intake should not exceed 150 mg/day in children and 250- 300 mg /day in 
adolescents. Even more important is the reduction of the intake of 
saturated fats eg butters fat, beef fat, palm oil and their replacement by 
monounsaturated and polyunsaturated fat such as natural oils. Some 
additional lowering of (LDL) may be achieved by the preferential use of 
vegetables over animal proteins and of complex carbohydrates over sugar 
since sucrose and fructose have a greater effect in raising blood levels 
than do other carbohydrates (69). 
              The reason for cholesterol lowering effect of polyunsaturated FAs is 
still not clear .However, several hypotheses have been advanced 
including the stimulation of cholesterol excretion into the intestine and it's 
oxidation to bile acids .Other hypotheses is the shift in distribution of 
cholesterol from the plasma into the tissues (58) . 
    1.8.2. Drug therapy  
               There are no major long term studies demonstrating harm or 
benefits of lipid lowering drugs. In general it should be restricted to children 
- 70  - 
 
with genetic disorders of lipid metabolism. Indications of drug therapy 
according to the (NCEP) program in children 10 yrs of age or older (after 
adequate trial of dietary therapy) include (85, 88): 
 1- LDL.C > 190mg/dl in patient with no CHD risk factor. 
 2- LDL.C >160mg/dl and  a positive family history of premature (CHD) or 
two or more of its risk factors after vigorous attempt had been made to 
control them .The goal is LDL.C <130 mg/dl in general and < 100 mg /dl in 
diabetics. Medical therapies for the common pediatric dyslipidemias are 
listed below (102): 
Table (3) 
Predominant 
lipid  
elevation 
Fredrickson 
phenotype 
Medications 
1st  Choice 2nd Choice 3rd  Choice 
LDL.C II A 
Bile acid 
binding 
resins  
Niacin  HMG –COA 
reductase  
inhibitor  
LDL.C + TG II B 
Niacin  Fibric acid  
derivatives 
/atorvastatin  
 
-------- 
 
TG IV 
Niacin  Fibric acid 
derivatives  
 
-------- 
 
 
1.8.2.1. Bile acids resins: 
        The (NCEP) recommends acid binding resins as the drugs of 
choice in treating high (LDL) in children. They block bile reabsorption 
from the gut resulting in bile excretion in stool. Compensatory 
hepatocytes bile synthesis increased which leads to increased 
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hepatocytes LDL-R expression and hence (LDL) clearance resulting in 
drop in its concentration. 
         The powder resin cholestyramine and cholestipole are insoluble in 
water and must be mixed with water or juice to avoid development of 
intestinal obstruction .The resins are divided between breakfast and 
dinner and are dosed in scoops or packets of 4-5g each. Typical dosing 
in children is to begin with 1-2 packets per day and increase every 
month to achieve (LDL) level < 130 mg/dl or until maximum is reached, 
24g in cholestyramine and 30 g in cholestipol. These drugs can lead to 
hypertriglyceridemia and therefore indicated for treating type IIA but not 
routinely type IIB (103). 
       1.8.2.2. Niacin: 
      Niacin is the second line drug. It is effective in patients with 
combined hyperlipidemia and in those with isolated 
hypertriglyceridemia resulting from elevated (VLDL) level. It appears to 
decrease lipoprotein production and increase its clearance. 
          Starting dose is 50 mg/day and increased gradually every 4 weeks 
or often less until (LDL) is < 160 mg/dl or (TG) is < 300mg/dl or until a 
dose of 1500 -2000mg /day is reached without liver toxicity. Splitting the 
dose should be attempted as soon as a dose of 100 mg/day is reached. 
Once (LDL) < 160mg/dl and (TG) < 300/dl no need to increase the dose. 
When (LDL) is < 130 mg/dl and (TG) < 125 mg/dl niacin dose can be 
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reduced or a trial period off medications can be attempted.  It has 
potentially significant systemic toxicity that include ;liver disease, GI tract 
upset and facial flushing .liver enzymes need to be measured every 3 
month in these patients  (104) . 
   1.8.2.3.. HMG – COA redductase inhibitor:  
        Consider use of this drug if the above two drugs failed or not 
tolerated. HMG-COA redductase catalyzes the conversion of HMG-
COA to mevalonate which is the rate limiting step in the synthesis of 
cholesterol. Inhibition blocks hepatocytes synthesis of cholesterol 
which stimulates hepatocytes to produce more (LDL) receptors leading 
to (LDL) clearance from the circulation .Food And Drug Administration 
(FDA) approved that statin is available since the year 2000. Examples 
of this group are lovostatin, pravastatin, simvastatin, fluvastatin and 
atorvastatin .Major complications are liver toxicity and rhabdomyolysis 
leading to renal failure (105). 
1.8.2.4. Fibric acid derivatives  
         This class inhibits lipoprotein production and increases its 
clearance. It is useful for treatment of a variety of dyslipidemias 
including type IIA, IIB IV and type V. usually given after the above 
mentioned drugs in treating type IIA but can be used after niacin in 
treating hypertriglyceridemias .No data exist on it's use in children 
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because safety and effectiveness are not established yet. Examples 
are Gemfibrozil and Fenofibrate (98). 
 
1.9. Studies Done on Lipid Profile: 
         Less is known about lipid abnormalities in diabetic children. Some 
studies have shown normal values two years after diagnosis while many 
others  have shown different results (106). 
              LDL and TC are higher in children with type1diabetes than their 
siblings (107) .This was proved by Tores M and his colleges in their study of 
141(58 males and 83 females) diabetic children and adolescents and their 
first degree relatives (1997). They found that mean concentration of (TC), 
(LDL) and ApoA1 were significantly higher in diabetic boys compared to their 
siblings (108). However, the Pittsburgh Diabetes clinic study found a difference 
between diabetic patients and their siblings in HDL.C sub-fraction but other 
lipid levels were not significantly different (109). 
         Lipid abnormalities are also common in diabetics than their controls 
(110)
. This was approved by some and rejected by other studies: The 
prevalence of dyslipidemia in children with type 1(DM) and it's relation to 
glycemic control was studied by K Azad, J M Parkin, M F court and M F laker  
in a group of 51 children and adolescents and a control population of 132 
school children. The prevalence of dyslipidemia in the diabetic group was 
39 % compared with 17% in the control group. Serum cholesterol alone was 
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raised in 25% of the diabetics and together with (TG) raised in 14% 
compared with 16% and 0.7 % respectively in control subject .Age has no 
effect in (TC) and (TG)  concentrations in children within the age range 
studied and there is a  positive correlation between (TC), (TG) and (HbA1c)  
in diabetic children .This confirm that glycemic control is a major factor 
affecting serum lipid concentration since that patients with good control have 
glycated (Hb A1c) similar to the control group (111) . Another study agreed 
upon these results where Plasma lipoproteins and lipoprotein lipase activity 
in 15 newly diagnosed diabetics 7-23 yrs old and their healthy control of the 
same age were evaluated in the year 1985 by Rubba P, Capaldo B and 
Caprio S.  They found that (TG), (VLDL) and (TC) were higher than in the 
control group and are inversely related to lipoprotein lipase activity. 
Decreased activity of the enzyme had been found to be associated with 
hypertriglceridemia and reduced (HDL) in young diabetic patients with 
ketonuria (112). 
     During a four weeks summer camp, A.Pollak .K, Widhalm, and 
E.Schober (1980) studied plasma lipoproteins and (HbA1c) in 19(8 
females and 11males) diabetics aged  2-12 years with a duration of 1-10 
yrs in comparison to 64 non diabetic control of similar age . All children 
took part in daily physical activities and received a modified diet. The 
mean (TG) was found to be significantly high in diabetic children on 
admission to the camp than the control. This difference is no longer 
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apparent at the end of the study .The mean (TC) and lipoproteins were 
similar in both groups though (TC) was significantly higher in diabetic 
females compared to diabetic males. HDL level;  which did not differ 
from control values, at the end of the study had increased significantly in 
diabetics to levels similar to those in the control group. No relationship 
was found between (HbA1c) estimates and (TG) or (TC) or between 
males and females (113). Similar results were shown when Serum 
lipoproteins and apolipoproteins were followed up in 34 children during a 
period of 5 yrs from diabetes onset in Sweden children (1997). Diabetics 
didn't differ from their control group in these respects but serum (TG) 
and (VLDL) were high in some diabetic patients and correlate 
significantly to subcutaneous fats and there was no correlation between 
any serum lipid and (HbA1c) (114). 
         Lipid abnormalities relate to metabolic control in some (107) but not 
all studies (115). The effect of glycemic control in lipid profile in  type 
1(DM) was studied by  Ercigas F, Arslan B and Uslu Y. Results showed 
that (TC) and (TG) were significantly higher than the control group and 
significantly increased  in poorly controlled in relation to metabolically 
well controlled diabetics (116).  
             The correlation between glycemic control and lipid metabolism 
in respect of possible risks for the development of macrovascular 
disease were studied by Thomer J and Klinghammer A (1993) in 78 
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diabetic children. There was no association between the quality of 
glycemic control and (LDL) or (HDL) and a week association with 
cholesterol .In nearly all patients (HDL) was estimated to be in the upper 
normal range (117). 
            Familial and dietary factors are important parameters in 
determining the lipid abnormalities. To determine whether abnormal lipid 
levels in children with type1diabetes are the result of poor metabolic 
control or genetic factors; Abraha A, James T  and their colleges 
conducted a study in 141 diabetics aged 7.7-19 yrs and 192 of their 
parents (1999). Nearly 15.3% had hypercholesterolemia, 17.9 % had 
hypertriglyceridemia and both were high in 5.6 %. Cholesterol, (TG) and 
(VLDL) were significantly related to glycemic control and familial factors 
may be important determinants of lipid levels in young diabetic people 
(118)
. This was not agreed upon in Adelaide at Australia where Esko J 
Wiltshire D, Craig H and Jennifer studied the relative influence of diet, 
metabolic control and familial factors on lipid in 79 diabetic children aged 
8 yrs and more and 61 age and sex matched control .Results showed 
that (TC), (LDL), (HDL) and Apo B were significantly higher in diabetics 
than in their control. cholesterol, (LDL) and Apo B show no difference 
between subjects with or without family history of premature (CHD) or 
lipid disorder and correlate independently with (HbA1c) but not with 
dietary control. Patients with high (LDL) >130 mg/dl had significantly 
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higher (HbA1c). They conclude that lipid abnormalities remain common 
in children with type1diabetes and were related to metabolic control but 
not dietary intake and can occur even in children who adhere to current 
dietary recommendations (119). 
            Lipid levels are shown to be affected by age and sex (120). Polka 
M, Souchan PF and Benali K (2000 ) studied  the relation between 
metabolic control , pubertal status and plasma lipoprotein levels in 126 
diabetic children with a mean duration of about 7-8 yrs  and their 
controls. Cholestrol of diabetics was higher in both sex and at each age 
than their control with a prevalence of 16% and was not correlated with 
the degree of metabolic control. The prevalence of hypertriglyceridemia 
was 5% in diabetics and was weekly positively correlated with the 
duration of (DM) and metabolic control. They conclude that plasma 
cholesterol levels are higher in diabetic children and don't follow the 
usual decreasing pattern during puberty (121). 
        Physical activity is one of the important risk factors controlling lipid 
levels. For this fact  Lipman   and his colleges conduct a  study to 
determine the prevalence and predictors of hypercholesterolemia and to 
examine the distribution and inter-relationship of risk factors for (CHD) in 
67 sub samples .They found that frequency of dyslipidemia was more 
than expected in the total sample and  (TC) – (CHD) risk factor 
associations were not observed. However, diabetes control and physical 
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activity were correlated with (TC). They conclude that assessing lipid 
profile in type 1diabetics and monitoring (CHD) risk factors in 
hyperlipidemic children is important (122). 
         Although most studies of lipids in children with type 1 diabetes 
have shown increased (TC) and (TG) (107), results for (HDL) have been 
conflicting some had found lower levels as Chase H (123) or normal levels 
(113)
. Whereas others found higher levels as RH Eckel, JJ alber and his 
colleges in their study of the components of (HDL) in diabetic patients 
and their control. HDL level was slightly higher than in the control (124). 
Another supporting study was that done by Anderson GE, and colleges 
on serum lipids and lipoproteins in 157 diabetics and 350 healthy 
reference individuals and it's relation to obesity. TG was lower while (TC) 
and (HDL) were higher in diabetics than their controls. Serum lipids and 
lipoproteins didn't correlate with obesity (113,125). 
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2. JUSTIFICATION AND OBJECTIVES   
  
 
2.1 Justification   
  
■  Diabetes mellitus is one of the major risk factors of lipid 
          disorders.                       
■  Early identification of lipid abnormalities aids in early management        
    and prevention of complications. 
■No similar study was done in Sudanese diabetic children. 
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2.2 Objectives     
 
  
  
       ■  To determine the prevalence of dyslipidemia in children with 
type 1 diabetes.              
               
  
  
       ■ To study the correlation between dyslipidemia  and some risk 
           factors. 
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3. PATIENTS AND METHODS 
3.1. STUDY DESIGN: 
 This is a cross- sectional, prospective, case control hospital based 
study. 
3.2. STUDY AREA: 
 The study was conducted in Khartoum State at diabetic clinics of: 
• Gaffer Ibn Auf Children Emergency Hospital, (Khartoum). 
• Ahmed Gasim Teaching Hospital, (Khartoum North). 
• Gaber Abu Eleiz Diabetes Center, (khartoum). 
3.3. STUDY PERIOD: 
 The study was conducted during a period of 6 months, from 
September 2004 January 2005. 
3.4 STUDY POPULATION: 
  Children diagnosed as type 1 diabetes aged < 18 years and their 
control groups were included. 
3.5. INCLUSION CRIETRIA: 
 • All children with type 1 diabetes < 18 yrs who came for follow up 
in the above mentioned referral clinics were enrolled in the study. 
 • Non-diabetic children matched according to age  group and sex 
were selected from schools as the control group. 
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3.6. EXCLUSION CRITERIA: 
 Diabetic patients and /or control were excluded in the following  
conditions: 
• Presence of acute illness 4-6 weeks prior to enrollment in the study   
including DKA. 
• Refusal of the child and /or their guardians to participate in the study. 
3.7. SAMPLE SIZE: 
The sample size was calculated according to the equation: 
N = Z2    PQ  
           d2 
Where 
N = sample size. 
Z = 1.96 (at 95th level of confidence). 
P = probability of the problem under study =o.95% . 
Q = 1- P = 0.05%. 
d = desired margin of error (o.1). 
At the 95th level of confidence N= 86. The total number of patients 
Studied were 100 ( total number of control  is 100). 
3.8. ETHICAL APPROVAL: 
 • Written approval of the study was obtained from the above 
mentioned hospital administrators. 
 • Informed consent was taken from children and /or their guardians. 
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3.9. STUDY TOOLS: 
3.9.1. Questionnaire: 
 A standardized questionnaire was designed which Included: 
Personal characteristics of the patient such as name, gender and 
ethnic group (125). Developmental history including schooling and 
exercise diabetes related variables such as duration of diabetes ,insulin 
dose and socio- demographic characteristics of parents.  Family history 
of  DM, obesity, CHD and hypertension were  also  included.  The  last  
section  contains   clinical examination  data  and  investigation  results. 
3.9.2. Clinical examination: 
   Every child was subjected to a clinical examination with emphasis        
 on weight using stand on  scale, height using unstretchable tape, blood 
pressure using Mercury sphygmomanometer with different cuff sizes and 
presence or absence of hepatomegaly and joint immobility. 
3.9.3. Investigations: 
3.9.3.1. Sample collection and storage: 
    All patients were requested to fast for at least 8 hours.  After 
sterilization using 70% alcohol, 3 ml of blood were withdrawn in a 
disposable syringe without applying tourniquet. One ml of whole blood was 
collected in (EDTA) labeled container for HbA1c testing. The remaining 2 
ml were centrifuged for 3 hours to extract plasma and then collected in a 
plane container for lipid profile testing. Both tubes were coded with serial 
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numbers and stored in the refrigerator at 2—8 C° to  be analyzed within 7 
days. 
3.9.3.2. Laboratory investigations: 
     HbA1c was preformed only to patients and determined on whole 
blood using colorimteric ion exchange column. The cut-off points used were 
those established by the (DCCT)as shown in (appendix 1). Specimens  for  
testing   lipid profile were analyzed  using  enzymatic  colorimetric  method  
in  which two control  materials  were  used ; control  level  1(normal)  and  
control level 2 (abnormal)as shown in (appendix 2). 
3.10 STATISTICAL METHODES: 
        Data was entered in computer using the Statistical Package of  
Social Science (SPSS). Frequencies were obtained for all variables and 
Chi square tests were computed for selected variables. The level of 
significance was taken as p < 0.05 and fissure exact test was used in 
frequencies of less than 5. 
3.11. POTENTIAL DIFFICULTIES: 
• Transport of samples to be centrifuged and stored. 
• Two referral clinics were conducted in the same day. 
3.12. INPUT OF THE AUTHOR: 
 The task of questionnaires completion, performing the clinical 
examination, collection of blood samples and entering the data in the 
computer were conducted by the author. 
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3.13. OTHER PARTICIPANTS IN THE STUDY: 
 Laboratory technicians in Gaber Abu Aleiz Diabetes Center 
participated a lot in this study together with colleagues in pediatrics. 
3.14. FUNDS AND GRANTS: 
The research was done with self resources with no external funds. 
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4. RESULTS 
 
A total number of 200 children were enrolled in the study .one 
hundred diabetic and the same number for control matched according to 
age group and sex. 
4.1. DEMOGRAPHIC CHARACTERISTICS OF THE STUDY 
GROUP. 
4.1.1. Age group: 
     The mean age of the study group was (12.1 yrs ± 2.5. SD for 
diabetics and 12.0 yrs ± 3.5.SD for control) and ranged from (3.5-18 yrs). 
The majority of children, 53 patients (53%), were in the age group 10 – 
14 yrs, in comparison to 77 controls (77%). While in the age group 15 – 
18 yrs were 25 diabetic (25%) and 12 controls (12%). In the age   group 
5-9 yrs there were 17 patients (17%) with their counterpart 9 (9%) 
controls. Only 5 diabetics (5%) and 2 (2%) of control were in the age 
group 1-4 yrs. The difference in age group distribution  between the two 
groups was statistically  insignificant,(P <0.5) as shown in (Fig 1).  
 4.1.2. Gender: 
Female gender constitutes about 56 of the study group (56%) while 
males constitute 44(44%) as shown in (Fig 2) 
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Figure 2. Gender distribution of the study group. 
 
  
 
  
                                                                                         (n=200) 
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4.1.3. Ethnic group: 
Arab ethnic group constituted the majority of the study group 69 
patients (69%) while the controls were 68 (68%). Ten of the patients 
(10%) and 9 of the controls (9%) were Nubians. Kordofanian and 
Darforian descendants were 9 patients (9%) and 16 controls (16%). Five 
patients (5%) and 3 controls (3%) were Bija, while 2 diabetics (2%) and 
3 controls (3%) were Nuba. Only one patient was from the Nilotic group, 
while 4 patients (4%) and one control were Equatorials. The difference in 
ethnicity was not statistically significant, (P=0.4) as shown in (Table 1).   
 
4.2. FAMILY AND SOCIAL HISTORY: 
4.2.1. Consanguinity. 
 In 39 patients (39%) there was no consanguinity between parents, 
compared to 50 controls (50%). First degree cousins were (35) 35% and 
(36) 36% for patients and controls respectively. Second degree 
consanguinity was found in 24% of the patients and only in 5 controls 
(5%). In two patients (2%) parents are far cousins compared to 9 
controls (9%). The overall difference between the two groups was 
statistically significant. (P=0.01) as shown in (Fig 3). 
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          Table 1. Ethnic origin of the study group.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
  Control 
N           % 
   Patient 
N            %  
Ethnic group origin 
 
 
  68         ( 68) 69          (69) Arab 
  09         ( 09) 10          (10) Nubian 
  16          (16) 09          (09) Kordofanian and Darforian 
  00          ( 00) 01          (01) Nilotic 
  03          ( 03) 05          (05) Bija 
  03          (03) 02          (02) Nuba 
   01         (01) 04           (04) Equatorial 
 100         100 100       100 Total 
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Figure 3. Parent consanguinity. 
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4.2.2. Parents education: 
  Father education (university and high school) was 41% and 46% in 
patients and controls respectively. Those who had basic and 
intermediate schooling were 43(43%) in the diabetic group and 38(38%) 
in the control group. Illiterate fathers were 16(16%) in each group. 
Illiterate mothers were 25 (25%) in patients and 28% in control. Only 4 
mothers (4%) had postgraduate education in diabetic group compared to 
7 mothers (7%) in the control group. The difference in education 
between the two groups was not statistically significant, (P = 0.6 and 0.1 
for father and mother education respectively), as shown in (Table 2, 3). 
4.2.3. Parents occupation: 
The majority of parents were labourers 68 (68%) and 72 (72%) for 
both patients and controls respectively. Government employee and 
businessmen were 29% in the patients group and 26% in the control 
group. The least were the unemployed parents; 3% for patients and 2% 
for control group. Most mothers were housewives, 92% in the patient 
group and 89% in the control group. Six mothers (6%) were government 
employee in both groups while only 2 mothers of diabetics and 4 of the 
controls were labourers. The difference was statistically insignificant,    
(P= 0.2 and 0.7 respectively), as shown in (Table 4, 5). 
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Table 2. Father education. 
 
p.value= 0.6 
 
Table 3.  Mother education.   
 
Level of education          Patient 
N                       % 
           Control 
N                          % 
Not educated 25                     ( 25)  28                        (28) 
Basic level 32                      (32)  25                        (25) 
Intermediate level 14                      (14)           24                        (24)   
Secondary level 25                      (25)  15                        (15) 
University level 04                      (04)  07                        (07) 
Total 100                   100 *99                         99 
 
P. value= 0.1  
 
 
* One mother died. 
 
 
Level of education 
 
Patient 
N                 % 
Control 
  N                 % 
Not educated 16              (16) 16               ( 16) 
Basic school 25              ( 25) 25               ( 25) 
Intermediate school 18              (18) 13               ( 13) 
Secondary school 29              (29) 27               ( 27) 
University level 12              (12) 19               ( 19) 
Total 100            100 100            100 
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Table 4. Father occupation. 
 
 
Occupation     Patient   
 N            %    
       Control 
     N               % 
Businessmen & professionals 12             (12)     16            ( 16) 
Government employee 17             (17)     10            (10) 
Skilled laborer 41             (41)     39            (39) 
Unskilled laborer 27             (27)     33            (33) 
Unemployed or retired 03             (03)     02            (02) 
Total 100           100     100          100 
 
P. value= 0.2 
 
 
 
 
 
 
 
Table 5. Mother occupation.  
 
Occupation 
 
 
            Patient 
  N                           %                
            Control 
      N                   % 
Government 
employee 
  06                        (06)      06                    ( 06) 
Housewife   92                        (92)      89                     (89) 
laborers   02                        (02)      04                     (04) 
Total  100                       100       *99                     99 
 
P. valu= 0.7 
 
 
 
* One mother died 
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4.2.4. Family history: 
Family history of diabetes mellitus was 51 (51%) and 55 (55%) in 
the patients and control group respectively. The difference was 
statistically not significant,(P=0.5). Family history of hypertension was 
41% in the patients group and 43% in the control group. Statistically the 
difference was not significant,(P=0.7). Seven patients had family history 
of (CHD) in comparison to 5 in the control group. The difference was 
statistically not significant,(P=0.5). History of obesity was found in 18% 
of  the patients group and only in 7% of the control group. Statistically 
the difference was significant,(P=0.01)as shown in (Table 6). 
 
4.3. CHILD EDUCATION: 
         4.3.1 Level of schooling: 
The majority of children were at basic school level, 63 patients (63%) 
and 72 control (72%), followed by secondary school ,26 patients (26%) 
and 25 control (25%). Five patients (5%) and 3 in the control group (3%) 
were at kinder-garden while 6 patients (6%) and none of the control 
group were not educated. Statistically the difference was not significant, 
(P= 0.4), as illustrated in (Table 7). 
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Table 6. Family history of the study group. 
 
            Study group   
 
Family history  
Case Control P. value 
No. % No. % 
Diabetes mellitus 51 (51)  55  (55) 0.50 
Coronary heart disease 07  (07) 05 (05) 0.50 
Obesity  18 (18)  07 (07) 0.01 
Hypertension  41 (41)  43 (43) 0.70 
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Table 7. Schooling level of the study group  
 
 
 
P value= 0.4 
 
Table. 8. School attendance of the study group.  
  
 
School attendance 
 
Patient 
N            % 
Control 
N                     % 
Regular 69               (64.8)           100                  ( 100) 
Interrupted 12                (11.2) 000                   000 
Stopped 13              ( 12.2) 000                    000 
 
Total 
 
 
94              94 
 
100                   100 
 
   
p.value< 0.05 
                                                                                                                                      
  
 
 
 
           Study group 
 
Schooling  
Patient Control 
No. %  No. % 
Not educated 06 (06) 00 (00) 
Kinder garden 05 (05) 03 (03) 
Basic 63 (63) 72 (72) 
Secondary 26 (26) 25 (25) 
Total 100 100 100  100 
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4.3.2. School attendance: 
Of the 94 diabetics attending school, twelve diabetics (11.28%) had 
interrupted schooling, 13(12.2%) stopped compared to none of the 
children in the control group. Regular attendance was found in 69(64.8%) 
diabetics and 100(100%) in the control group. This was statistically 
significant, (P <0.05) as demonstrated in (Table 8) 
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4.4. EXERCISE: 
Most of the children in both groups were physically active, 62% of 
patients and 55% of the control. This was not statistically significant,        
(P= 0.3), as illustrated in (Fig 4 ). 
 
4.5. DIABETES MELLITUS VARIABLES. 
4.5.1. Duration of diabetes: 
Newly diagnosed diabetics of <1years were 23%. The majority of 
patients 45% had diabetes for 1-5 years while 24% had it for 5-9 years. 
Duration of > 9years was found in only 8% of patients(Fig 5). 
 
         4.5.2. Type of insulin: 
 Only two patients (2%) use soluble insulin alone. A dose of 0.05-1 
U/kg/d was used by 66% of diabetics. Those who require a dose <0.05 
were 13% while 21% use a dose of 1-2 U/kg/d(Table 9). 
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Figure 4. Exercise  performance of the study group (DM). 
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5 Figure. Duration of diabetes.   
  
  
  
  
5 Figure. Duration of diabetes.   
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Table 9.  Insulin dose. 
 
 
Insulin dose No. % 
<0.5 U/Kg 13  (13) 
0.5-1 U/Kg 66 (66) 
1-2 U/Kg 21 (21) 
Total 100 100 
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4.6. ANTHROPOMWTWRIC MEASURES: 
4.6.1. Weight 
Twenty nine diabetics (29%) and 25 controls (25%) were at < 3rd 
centile.  Nine diabetics (9%) and 4 of the control  group (4%) were at < 
5th centile, 6(6%) diabetics and 11(11%)of the control group were at < 
10th centile and 25(25%) diabetics and19 of the control group (19%) 
were at < 25th centile. At < 50th centile there were 22(22%) diabetics and 
15(15%)of the control group while 5(5%) diabetics and 14(14%) of the 
control group were at < 75th centile. Three diabetics (3%) and 10 in  the 
control group (10%) were at < 90th centile while none and 1 (1%) of 
diabetics were at < 95th and 97th centiles compared to 1(1%) of the 
control group at each centile respectively.  None of diabetics or the 
control were at > 97th centile. The difference was statistically insignificant,  
(P = 0.4) as shown in (Fig 6).              
4.6.2. Height. 
       In both groups 18 children (18%) were at < 5th centile while 7 
children (7%) were at the 5th centile. Ten in control group (10%) and 13 
diabetics (13%) were at < 10th centile while 20(20%) diabetics and 
18(18%)of control group were at < 25th centile. Diabetics at < 50th and 
75th centiles were 21(21%) and 11(11%) compared to control group 
18(18%) and 16(16%) in the same centiles respectively. Six diabetics  
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Figure 6. Weight centile of the study group. 
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(6%) and 7 controls (7%) were at < 90th centile while 4 diabetics (4%) 
and 6(6%) controls were at < 95th centile. The difference was statistically 
insignificant, (P= 0.9) as demonstrated in ( Fig 7).  
 
4.6.3. Blood pressure: 
In both groups 50 children (50%) had BP <50th centile, while 34 
patients (34%) and 28 controls (28%) were at the 50th centile. Eleven 
patients (11%) and 17(17%)of the control group were at the 75th centile. 
Three patients (3%) and 5(5%) of the control group had BP at the 90th 
centile and only two diabetics and none of the control group fall in the 
95th centile. There was no  statistically significant difference,(P= 0.3) as 
shown in( Fig 8). 
 
4.6.4. Sexual Maturity Rate (SMR).  
Fifty (50%) of the diabetics were in stage1 compared to 48(48%) of 
the control  group. At stage 2 and 3 there were 9(9%) and 14(14%) 
diabetics respectively compared to 22(22%) and 7(7%)of the control  
group. At stage IV there were 8 (8%) patients and 8(8%)of  the control 
group while those at stage v were 20 patients (20%) and 15 of the 
control group (15%). The difference was not statistically significant, (P = 
0.08) as shown in (Fig 9) 
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Figure 7. Height centiles of the study group graph. 
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Figure 8.  Blood pressure of the study group. 
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Figure 9. Sexual maturity rate of the study group. 
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4.7. INVESTIGATIONS: 
4.7.1. Glycosylated HbA1c: 
        Good glycemic control (HbA1c) was found in 43 (43%) of 
patients and distributed as, non diabetic level (4.4- 6 %) was found in 8 
diabetics (8%). Four (4%) had a goal level (6- < 6.5%) and 31(31%) had 
good control (6.5- 8%), While diabetics with action suggested levels (> 8) 
were 57(57%)as  shown in(Table 10). 
 
4.7.2. Prevalence of dyslipidemia: 
Dyslipidemia was found in 43% in the diabetic group and 21% in 
the control group. This difference was statistically significant, (P <0.001), 
as shown in (fig 10).  
Cholesterol was abnormal (border line and elevated) in 37% of the 
diabetics; it was elevated in 10 patients (10%) and borderline in 27  
(27%), compared to 4 elevated levels and 13 borderline levels in the 
control group. The difference was statistically significant, (P= 0.01). 
Triglyceride level was high in 16 patients (16%) compared to 7 (7%) 
of the control. The difference was statistically significant (P< 0.04). 
 LDL was elevated in 28 diabetics (28%) while only 2 (2%) of the 
control had elevated levels. The difference was statistically significant, 
(P< 0.00).  
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HDL was low in 7 diabetics (7%) and none of the controls. The 
difference was statistically significant,(0.007), as shown in (Fig11). 
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Figure10. Prevalence of dyslipidemia of  the study group. 
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Fig 11.  Prevalence of individual dyslipidemia of the study group. 
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4.8. CORRELATION BETWEEN LIPID ABNORMALITIES AND RISK 
        FACTORS. 
4.8.1. Glycosylated HbA1c:  
Patients with good glycemic control and abnormal cholesterol level 
were 15(25.4%) compared to 21(53.8%) with poor glycemic control and 
abnormal lipids. This difference was statistically significant,(p<.0.01).  
Four patients (6.8%) with elevated (TG) had good glycemic control 
in comparison to 12(30.8%) with poor control. The difference was 
statistically significant, (p <0.05). 
Patients with abnormal (LDL) and low (HDL) with good glycemic 
control were 12 (20.3%) and 2 (3.4%) respectively compared to 15 
(38.5%) and 5 (12.8%) with bad glycaemic control. The difference was 
statistically insignificant,(p= 0.1) for both as shown in (Fig 12).  
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Figure 12. Correlation between dyslipidemia and glycosylated 
HBAIC/patient. 
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4.8.2. Duration of diabetes mellitus: 
Patients with diabetes duration < 1 yr and abnormal cholesterol 
were 8 (34.8%) compared to 10(22.2%) with 1-5 yr duration. Diabetes 
duration of 5-9 yrs and abnormal cholesterol was found in 14(58.3%) 
while in only 5(5%) patients with abnormal cholesterol had diabetes for > 
9yrs.statistically, the difference was significant,(p<0.01). Diabetes 
duration of < 1yr and abnormal (LDL) was found in 5 patients (21.7%) 
compared to 9 diabetics (20%) with 1-5 yrs duration. Eight patients 
(33.3%) had a duration of 5-9 yrs and 6(75%) had it for > 9yrs. This 
difference was statistically insignificant (p= 0.1).  
Patients with diabetes duration < 1 yr and elevated triglycerides 
were 4 (17.4%) compared to 6 (13.3%) with 1-5 yr duration. Diabetes 
duration of 5-9 yrs and elevated (TG) was found in 6 (25%) while none 
of the diabetics with > 9yrs duration had elevated (TG).statistically the 
difference was not significant,(p=0.3). None had diabetes duration of < 
1yr and low (HDL). Four patients (8.9%) with low (HDL) had diabetics for 
1-5 yrs duration compared to 2 patients (8.3%) and only 1 (12.5%) with 
diabetes duration of 5-9 yrs and > 9 yrs respectively. This difference was 
statistically insignificant,(p=0.4)as shown in (Fig 13). 
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Fig 13. correlation between dyslipidemia and duration of diabetes. 
 
                                                                                          (n =100) 
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4.8.3. Exercise:  
• Cholesrtol level: patients with abnormal cholesterol who 
performed exercise were 20(32.3%) in comparison to 17 (44.7%) 
who didn't, while 6controls (10.9%) performed exercise and 
11(24.4%) didn't. The difference was not statistically significant for 
both groups,(p=0.2) for patients and (p=0.07) for control.  
• Triglyceride level: seven diabetics (11.3%) with elevated TG 
exercised compared to 9 (23.7%) didn't. while the 7 (12.7%) of the 
control with elevated TG performed exercise. The difference was 
insignificant(p=0.1).  
• LDL level: Diabetics with elevated LDL and performed exercise 
were 12(19.4%) in comparison to 16(42.1%) with no exercise. Only 
2 (3.6%)of  the control group with elevated LDL exercised. The 
difference was statistically significant for diabetics(p<0.01) and not 
for the control  group (p=0.1). 
• HDL level: Three diabetics (4.8%) with low HDL performed 
exercise compared to 4 (10.5%) with no exercise and none of the 
controls, the difference was statistically insignificant, (p=0.2) as 
shown in (Table 11 &12) 
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4.8.4. Gender: 
Cholesterol: Male diabetics who had abnormal cholesterol were 
15(34.1%) compared to 22 diabetic females (39.3%), while only 7 of the 
control group (15.9%) were males and 10 females (17.9%). The 
difference was statistically insignificant for both  patients(p=0.5) and the 
control  group (p=0.7). 
Triglycerides: Four diabetic males (9.1%) compared to 12 females 
(21.4%) had elevated TG, while 3 males (6.8%) in the control group and 
4 females (7.1%) had elevated TG. The difference was statistically 
insignificant. 
LDL level: Ten males (22.7%) and 18 females (32.1%) had 
elevated (LDL) compared to 2 male of the control  group (3.6%). The 
difference was statistically insignificant,(p=0.2) for both groups.  
HDL level: Two Males (4.5%) had low (HDL) compared to 5 
females (8.9%), while none of the control group had low (HDL) This 
difference was statistically insignificant(p=0.3). As shown in (Table 13, 
14) 
 
4.8.5. Age group: 
Cholesterol level: Three diabetics (60%) with abnormal cholesterol 
were at age group 1-4 yrs compared to none of the control group. Six 
diabetics (35.3%) and only one(11.1%)of the control  group were at age  
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group 5-9 years. At age group    10 -14, there were 17 diabetics 
(32.1%) and 13 of the control group (16.9%) while, 11 patients (44%) 
and 3 of  the control group (25%) were at age group 15-18 yrs. The 
difference was not statistically significant (p=0.5 ) for patients and (p=0.7) 
for the control group. 
Triglyceride level: One diabetic (20%) at age 1- 4yrs had elevated 
TG compared to none of controls. Two diabetics (11.8%) and one 
control (11.1%) were at age group 5-9yrs while, 6 diabetics (11.3%) and 
6 controls (7.8%) were at age group 10-14yrs. Those aged 15-18yrs 
were 11 patients with none of controls. The difference was 
insignificant,(p=0.2, p=0.7) for patients and control respectively. 
LDL level: Two diabetics (40%) at age group 1-4 yrs, 3 (17.6%) at 
age 5- 9 yrs had abnormal LDL compared to none of their controls. 
Fifteen diabetics(28.6%) and 2 controls (2.6%) were at age group 10 -14 
yrs while eight diabetics (32%) and none of controls  were at age group 
15-18yrs. The difference was statistically insignificant,(p=0.6 , p=0.8) for 
patients and control respectively. 
HDL level: Two diabetics (11.8%) at age group 5-9 yrs, 1(1.9%) at 
10-14yrs age group and 4 (16%) at 15-18yrs group had low HDL 
compared to none of the controls. Statistically the difference was 
insignificant,(p=0.1). (Table 15.16) 
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Table 13.  correlation between dyslipidemia and age group in  years 
                In the   Patients.z 
 
 
Age group 1-4yr 5-9 yr 10-14 yr 15-18 yr p.value 
Dyslipidemia No        % No        % No       % No        %  
 
TC 
 
03     (60) 06      (35.3) 17     (32.1) 11     (44) 0.5 
 
TG 
 
01     (20) 02      (11.8) 06     (11.3) 07      (28) 0.2 
 
LDL 
 
02     (40) 03      (17.6) 15      (28.3) 08      (32) 0.6 
 
HDL 
 
00     (00) 02      (11.8) 01      (01.9) 04     (16) 0.1 
 
 
 
 
Table 14.   correlation between dyslipidemia and age group in  
years in the Control group. 
                    
Age group   1-4yr    5-9 yr 10-14 yr 15-18 yr p.value 
Dyslipidemia No        % No        %      No       % No        %  
 
TC 
 
00     (00) 01     (11.1) 13     (16.9) 03     (25) 0.7 
 
TG 
 
00     (00) 01      (11.1) 06     (07.8) 00      (00) 0.7 
 
LDL 
 
00     (00) 00      (00.0) 02      (02.6) 00      (00) 0.8 
 
HDL 
 
00     (00) 00      (00.0) 00      (00.0) 00      (00) - 
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4.8.6. Blood pressure  
• Cholesterol: Seventeen diabetics (34%) and 12 (24%) of  the 
control group with blood pressure < 50thcentile had abnormal 
cholesterol. Three of  the control group (10.7%) and 14 diabetics 
(41.2%) with abnormal cholesterol were at 50th centile. Three 
diabetics (27.3%)  where at the 75th and 3 (100%) at the 90th 
centile had abnormal cholesterol in comparison to none of  the 
control. The difference was statistically insignificant 
• Elevated TG:  In both groups 5 children (10%) had BP < 50th 
centile while, 8 diabetics (23.5%) and 2 of the control group (7.1%) 
were at the 50th centile. One patient at each of the 75th (9.1%), 90th 
(33.3%) and 95th (50%) had elevated TG compared to none of  the 
control. The difference was statistically not significant. 
• Abnormal LDL: Eleven diabetics (22%) and only two of the  
control group (3%) with abnormal LDL were at < the 50th centile 
compared to 12 diabetics (35.3%) and only one  of the control  
group (3%) at the 50th. Two diabetics (18.2%) and (66.7%) at each 
of the 75th and 90th centile had abnormal LDL compared to none of 
control. At the 95th centile there was one patient (50%) compared 
to none among the control. Statistically this difference was not 
significant 
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• Low HDL:  Two diabetics (41%) were at < 50th centile compared to 
4 (11.8%) at the 50th and only one (33%) at the 90th centile and 
none of the control  group had low HDL as shown in(Table 17, 18) . 
The difference was statistically insignificant.  
4.8.7. Sexual Maturity Rate (SMR). 
• Abnormal cholesterol level: Eighteen diabetics (36%) and 7 
of the control group were at stage 1. Four diabetics (44.4%) 
and 4 of the control group (18.2%) were at stage II. Five 
diabetics (35.7%) and 2 of the control group (25%) were at 
stage III. In stage IV and V there were 2(28.6%) and 8(40%) 
diabetics respectively and two for stage IV (25%) and V 
(14.3%) of the control group.   
• Elevated TG:  Six diabetics (12%) and 3 of the control (6.3%) 
were at stage I compared to only one diabetic (11.1%) and 2 
of the control (9.1%) at stage II. Four diabetics (28.6%) were 
at stage III while only one of the control group (12.5%) was in 
the same stage. Diabetics in stage IV and V were 3(42.9%) 
and 2(10%) respectively compared to none in stage IV and 
only one of  the control  group (7.1%) in stage V. The 
difference was statistically insignificant. 
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Table 15. correlation between dyslipidemia and  blood pressure in  
The patients. 
Blood 
pressure 
  <50th 
 
 
   50th   75th 90th 95th p.value 
Lipid  
 
No        % No        %      No       % No        % No       % 
 
 
   TC 
17     (34) 14     (41.2) 03     (23.7) 03    (100) 00      (00)    0.1 
 
   TG 
05     (10) 08      (23.5) 01     (09.1) 01   (33.3) 01      (50)    0.2 
 
   LDL 
11     (22) 12      (35.3) 02      (18.2) 02   (66.7) 01      (50)    0.2 
 
   HDL 
02     (04) 04      (11.8) 00      (00.0) 01      (50) 00     (00)    0.1 
 
 
 
 
Table 16.  Correlation between Dyslipidemia and Blood pressure in  
              The Control group. 
 
Blood 
pressure 
  <50th 
 
 
   50th   75th 90th 95th p.value 
Lipid  
 
No        % No        %      No       % No        % No       % 
 
 
   TC 
12     (24) 03     (10.7) 02    (11.8) 00    (00) 00      (00)    0.2 
 
   TG 
05     (10) 02      (07.1) 00     (00.0) 00    (00) 00     (00)    0.5 
 
   LDL 
01     (02) 01      (03.0) 00      (00.0) 00    (00) 00      (00)    0.8 
 
   HDL 
00     (00) 00      (00.0) 00      (00.0) 00      (00) 00     (00)    -- 
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• Abnormal LDL:   Diabetics at stage I were 12(24%) 
compared to none of the control. Three diabetics (33.3%) and 
only one of control (4.5%) were at stage II. Four diabetics 
(28.6%) and only one  of the control group(12.5%) were at 
stage III. One (14.3%) and 8 (40%) diabetics were at stage IV 
and V respectively compared to none of the control  group. 
The difference was statistically insignificant.  
• Low HDL level: Two diabetics (4%) and (14.3%) were at 
stage I and III respectively. One diabetic at each of stage II 
(11.1%), stage IV (14.3%) and stage V (5%) compared to 
none of the control group as shown  in(Table 19,20). The 
difference was statistically insignificant.   
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Table 17. Dyslipidemia- Sexual Maturity Rate (SMR) correlation in  
                 Patients. 
 
  
  
  
  
 
Table 18.  Dyslipidemia -  sexual maturity rate (SMR) correlation in  
  
                 Control group. 
 
Blood 
pressure 
  <50th 
 
 
   50th   75th 90th 95th p.value 
Lipid  
 
No        % No        %      No       % No        % No       % 
 
 
   TC 
07   (14.6) 40    (18.2) 02    (25.0) 02    (25) 02      (14.3)    0.9 
 
   TG 
03   (6.30) 02      (09.1) 01    (12.5) 00    (00) 01     (7.10)    0.8 
 
   LDL 
00   (00.0) 01      (04.5) 01      (12.5) 00    (00) 00      (00)    0.1 
 
   HDL 
00     (00) 00      (00.0) 00      (00.0) 00      (00) 00     (00)    -- 
 
  
    
SMR   Stage I 
 
   Stage II   Stage III Stage IV Stage V p.value 
Lipid  
 
No        % No        %      No       % No        % No       % 
 
 
   TC 
17   (36.6) 04     (44.4) 05    (35.7) 02   (28.6) 08      (40.3)    0.9 
 
   TG 
05   (12.0) 01      (11.1) 04     (28.6) 03   (42.9) 02      (10.0)    0.1 
 
   LDL 
11   (24.0) 03      (33.3) 04      (28.6) 01   (14.3) 08      (40.0)    0.6 
 
   HDL 
02   (04.0) 01      (11.1) 02      (14.3) 01   (14.3) 01     (05.0)    0.5 
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     4.8.8. Family history:  
Correlation between lipid profile and family history of (CHD) and 
obesity as risk factors were as follows:  
• Abnormal cholesterol:  
• Three diabetics (42.9%) had family history of (CHD) compared to 
none of the control group. Thirty four diabetics (36.6%) and 17 of 
the control group (17.9%) had no family history of (CHD. 
Statistically this difference was not significant(p=0.7) and (p=0.2) 
for patients and control respectively. 
• Six diabetics (33.3%) compared to none of the control had family 
history of obesity. Thirty one diabetic (37.8%) and 17 of the control 
(17.9%) had no family history of obesity. The difference was not 
statistically significant, (p=0.7) for the patients and (p=0.2) for the 
control group. 
• Elevated TG: All children in the study with elevated TG had no 
family history of (CHD). One diabetic (5.6%) and only 1 control 
(6.14.3%) had a positive family history of obesity compared to 15 
diabetics (18.3%) and 6 of  the control (6.5%) with negative history. 
The difference was statistically not significant.  
• Abnormal LDL level: Two patients (28.6%) and none of the 
control had family history of (CHD) compared to 26 patients (28%) 
and 2 of the  control (2.1%) had not, with statistically insignificant 
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difference. Six diabetics (33.3%) and none of the controls with 
abnormal (LDL) had family history of obesity compared to 22 
diabetics (26.8%) and 2 of the control (2.2%) who hadn’t, 
Statistically the difference was not significant. 
• Low HDL level: One diabetic (5.6%) had low (HDL) and family 
history of obesity compared to none of the control. The difference 
was statistically insignificant, as shown in (Table 21, 22, 23, 24). 
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 Table 19.   Correlation between dyslipidemia and  family history    
                    Of coronary heart disease in patients. 
 
Family history of CHD positive negative 
p.value Dyslipidemia 
 
No        % No        %       
 
   TC 
03     (42.9) 34     (36.6) 0.7 
 
   TG 
00     (00.0) 16      (17.2) 0.2 
 
   LDL 
02     (28.6) 26      (28.0) 0.9 
 
   HDL 
00     (00.0) 07      (07.5) 0.4 
 
 
 
 
 
 
 
 
Table 20.  Correlation between dyslipidemia and family history of      
                   Of coronary heart disease in control group.  
 
Family history of CHD positive negative 
p.value Dyslipidemia 
 
No        % No        %       
 
   TC 
00     (00) 17     (17.9) 0.2 
 
   TG 
00     (00) 07      (07.4) 0.4 
 
   LDL 
00     (00) 02      (02.1) 0.7 
 
   HDL 
00     (00) 00      (00.0) -- 
 
 
 
 
 
 
 
 
- 135  - 
 
Table 21.  Correlation between dyslipidemia and family history of 
                  Obesity in patients. 
 
Family history of obesity positive negative 
P.value Dyslipidemia 
 
No        % No        %       
 
   TC 
06     (33.3) 31    (37.8) 0.7 
 
   TG 
01     (05.6) 15      (18.3) 0.1 
 
   LDL 
06     (33.3) 22      (26.8) 0.5 
 
   HDL 
01     (05.6) 06      (07.3) 0.7 
 
 
 
 
 
 
Table 22.  Correlation between dyslipidemia and family history of  
                  Obesity in control group. 
 
Family history of obesity positive negative 
P.value Dyslipidemia 
 
No        % No        %       
 
   TC 
00     (00.0) 17     (18.3) 0.2 
 
   TG 
01     (14.3) 06      (06.5) 0.4 
 
   LDL 
00     (00.0) 02      (02.2) 0.6 
 
   HDL 
00     (00.0) 00      (00.0) -- 
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DISCUSSION 
5.1. DEMOGRAPHIC CHARACTERISTICS: 
        5.1.1. Age group: 
        The age of children in the study ranged from 3.5 - 18 yrs 
covering most of the childhood period, the  same as in studies done in 
diabetic children in Australia and in none diabetic Saudi children (80,113). 
Other studies covered only certain age group (78, 79). Two groups 
dominated; first the age group 10-14yrs (53%) and  15-18yrs comprising 
(25%)  representing pubertal years and the second was the age group 5-
9yrs ( 17%) mostly school children, a result which coincides with the 
literature which described two peak age of childhood diabetes (14)  
        5.1.2. Gender: 
        Females outnumbered males in this study, F: M was 1.27: 1.0, 
a result that goes with other studies  and contradicts the study done by 
Pol lak Kin in which males outnumbered females ( 1 0 8 , 1 2 7 , 1 1 3 ) .   
        5.1.3. Ethnic group:  
        There was a wide variation in different ethnic group origin with 
the predominance of Arab in both groups. This finding may reflect the 
multi-ethnic community and the population structure of  the national  
capital Khartoum, where the study was conducted. it may also indicate 
ethnic differences  in the prevalence of type 1 diabetes (13,126). 
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5.2. FAMILY AND SOCIAL HISTORY: 
       4.2.1. Consanguinity: 
         Consanguinity was observed among the majority of parents in 
both groups constituting 61%.  In the diabetic group this may raise the 
point of genetic factors as a risk factor. This  should be taken with 
caution since a consanguineous marriage is a common practice in our 
community (4, 17,118). 
5.2.2. Parent education: 
  The majority of parents were educated, 84% of fathers and 77% of 
mothers. This finding has an important impact on parent's knowledge 
and communication with the sources of information and management of 
their diabetic children (4,5) . 
       5.2.3. Parent  occupation: 
       The majority of fathers were either skilled or unskilled laborers 
giving reflection of their poor monthly income. The same findings were 
reported in a study done by Zaki, while the  majority of mothers were 
housewives adding no more to the family income.  On the other hand, 
this can be taken as an advantage by the more time available to look 
after their children (128). 
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5.3. CHILD EDUCATION 
       4.3.1. Level of schooling: 
        Only six diabetics (6%) hadn't attended the school and this was 
attributed to over protection for them by their parents since diagnosis. 
Similar results (7%) were encountered by Mohammed A in his study of 
knowledge, attitude and practice among diabetic children (129)  
       5.3.2. School attendance: 
           Diabetics in the study had irregular  school attendance in 
13% while 12% stopped schooling. Similar results  were reported by 
Mohammed A, 14% stopped schooling while 38% had irregular 
attendance(129). The importance of child education is a major issue since 
higher education level of the diabetic patients was found to be 
associated with better knowledge regarding diabetes as reported in the 
above mentioned study. 
 
5.4. EXERCISE 
        Most of children perform physical activity, a  required  practice 
to maintain acceptable blood glucose and lipid levels according to the 
National Cholesterol Education Program(NCEP) guidelines and other 
studies (5, 41, 85, 122). 
 
 
- 140  - 
 
5.5. DIBATES MELLITUS VARIABLES 
    5.5.1. Duration of diabetes: 
        Duration of diabetes in this study was < 1 yr - > 9yrs (maximum 
13 years), a similar duration was found in the study done by Pollak K (113). 
Diabetics with duration > 9yrs were 8% in our study and they were the 
group who needs special attention looking after complications. Since 
long diabetes duration and social background were found to be well 
related to the development of complications as demonstrated by Daoud 
in his study and mentioned in the literature (5,130).         
   5.5.2. Insulin dose: 
         A dose of 0.5-1 u/kg/ d  was used by 2/3 of diabetics while 1/5 
used a dose of 1-2 u/kg/d reflecting the metabolic control of the diabetics 
in the study. These results were in line with both the literature on insulin 
dose in preadolescents and teenagers (4). 
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5.6. ANTHROPOMETRIC MEASURES  
        5.6.1. Weight: 
        The weight centile distribution of both groups showed no 
difference which can be attributed to their similar social class. No cases 
of overweight were detected reflecting the absence of weight effect on 
lipid profile abnormalities as reported by Anderson GE (125). 
        5.6.2. Height: 
In both groups 18% were below the 5th centile (stunted) with no 
difference in other height centiles. Similarities in both groups may refute 
the role of diabetes on height in this study, since the effect of diabetes 
on height leading to growth failure is well recognized  in the literature. In 
this study these percentages were lower than those reported by Zaki, 
40% in diabetic children and may point to improvement in diabetes 
control (5, 128).  
   5.6.3. Blood pressure: 
        The majority of children had normal blood pressure. Five  
children  in the Control group and 3 diabetics (3%) were at the 90th 
centile and 2 diabetics were at the 95th centile. This result demonstrated 
the importance of regular blood pressure monitoring as recommended 
by[NCEP] and vigorous control of BP and lipid abnormalities as 
concluded by Orchad TJ (79). 
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5.6.4. Sexual maturity rate: 
        Most of children were preadolescents and there was no 
difference in the two groups regarding the stages of puberty to point to 
diabetes role since diabetes can cause delayed puberty as mentioned in 
the literature (5). 
5.7. INVESTIGATIONS  
        5.7.1. Glycosylated HbA1c: 
         Diabetics with good glycemic control were 59% in 
contradistinction to the findings of Zaki who found poor glycemic control 
in 58.8% of the diabetics studied. This can be explained in part with the 
exclusion criteria in our study of patients with (DKA) who were included 
in her study (128).  
        5.7.2. Prevalence of dyslipidemia: 
        Prevalence of dyslipidemia was found to be 43% in diabetics 
and 21% in the control group. This was higher than the prevalence found 
by K Azad 39% in diabetics and 17% in control and lower than that of 
Saudi non diabetic children of 9% (80,111). These results demonstrated 
that dyslipidemia was common in diabetics than their controls and were 
similarly common in many studies (108,112,116,119,122) and not in line with 
others (109,113,114).  
       Prevalence of hypercholesterolemia was 10% in diabetics which 
was lower than the results found by Abraha A (15.3%) and Polka M 
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(16%)  (118,121). Prevalence of hypercholesterolemia in controls was 4% 
which was lower than the results of Navars study (21.7%) and higher 
than that of Saudi children (1.55%) (80, 81).      
        Prevalence of hypertriglyceridemia was16% which was lower 
than the prevalence found by Abraha A (17.9%) and Pollka M (5%)(118)  
(121)
. In the control group the prevalence of 4% was higher than that of 
Saudi children (1.96%) (80)  . In this study HDL was found to be lower in 
diabetics than their controls,  the same   result was reported by Chase H 
(123) while others reported either high or normal levels of HDL 
(117,119,124,125) 
. 
 
    Results of this study demonstrated increased prevalence of 
dyslipidemia in Sudanese diabetics and non diabetics. Explanations for 
this can be: first due to the fact that diet is an important operative factor 
causing hyperlipidemia was not addressed in this study. Secondly race 
and geographical distribution may play a role, since they affect lipid 
profile as reported in the literature and finally this study included all lipid 
profle variables in comparison to other studies which concentrated 
mainly on the levels of(TC) and( TG). 
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5.8. CORRELATION BETWEEN LIPID PROFILE AND RISK 
        FACTORS 
        5.8.1. Glycosylated HbA1c: 
        Both (TC) abnormalities and hypertriglyceridaemia were positively 
correlated with metabolic control using (HbA1c); same results were 
reported in many studies (111,113,116,118). Both (LDL) abnormalities and low 
(HDL) had no association with HbA1c in this study, similar results were 
reported by Thomer J (117,119). The effect of( HbA1c) on the development 
of lipid disorders is well known in the literature (49).   
       5.8.2. Duration of diabetes: 
        Both (TC) and ( LDL) dyslipidemias were positively correlated with 
the duration of diabetes mellitus with increasing abnormalities with 
increased duration. Similar results were reported by Polka M (121).  Part 
of this can be explained by the increased metabolic derangements and 
complications ( hyperlipidemia is one of them) with increased duration 
(3,51). 
        5.8.3. Exercise: 
 In this study there was positive correlation between exercise and (LDL) 
level. while Lipman found a positive correlation with TC (122). The effect of 
exercise on lowering blood lipid levels was addressed by many  studies 
(5, 68, 85)
.  
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  5.8.4. Gender: 
        Female gender showed positive correlation with (TG)level. 
Although there was no association with other lipid profile, the percentage 
of lipid abnormalities increased in females compared to males. These 
were similar to Polka M results and in  contradiction to those of  Plolak K 
(121)
 
(113)
. 
5.8.5. Age group: 
        Age had no effect on lipid profile; similar results were reported by K 
Azad and Orchad TJ,This in contradistinction to findings of the study on 
Saudi children where the highest mean of (TC) was in the age 3-4 years 
old and a significant decrease occurred with age , with lowest mean in 
those 14-15 yrs old (79) (80) . 
     5.8.6. Blood pressure: 
         Although blood pressure had no effect on lipid profile in the 
study, Orchad TJ, in his study ,concluded the importance of vigorous 
blood pressure control. He also  reported that complications of diabetes 
and  hyperlipidemia were  more with  systolic blood pressure  > 120 
mmHg and diastolic blood pressure of > 80mmHg ( 79). 
        5.8.7. Sexual maturity rate: 
        Puberty had no effect on lipid profile and there was loss of the 
decreasing lipid abnormality with puberty. Similar results were reported 
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by Polka M and conflicting results were found in the Navara study and 
the study of Saudi children. The effect of puberty can be related to the 
sexual maturation and related hormone levels in this period as stated by 
Al-Hazemi in his study (121, 81, 80).   
 5.8.8. Family history: 
        Lipid profile showed no difference between children with or without 
family history of (CHD) or obesity, a result similar to those found by Esko 
J, while Abraha A found significant relation between familial factors and 
lipid profile (118) (119). 
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CONCLUSION 
 
 Prevalence of dyslipidemia was found to be higher in 
diabetics than their control. 
 Prevalence of hypertriglyceridemia was observed to be the   
highest in relation to other lipid profile variables and showed 
higher percentages in female gender.    
 Dyslipidemia of total cholesterol and (LDL) have positive 
correlation with (HbA1c) and increased with poor glycemic 
control. 
 Risk factors positively correlated with lipid profile are 
duration of diabetes mellitus, metabolic control and exercise. 
 Both Sexual maturity rate and blood pressure have no effect 
on lipid profile. However, there is increasing percentage of 
hypercholesterolemia with increasing blood pressure and 
advance in (SMR) in the patient group. 
 Family history of obesity and coronary hear disease has no 
effect on lipid profile. 
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                         RECOMMENDATIONS 
 It is extremely important to develop a national   diabetes 
program for lipid screening. 
 
 Education of children and their families about the dietary 
guidelines  is recommended for all children. Addressing 
its role in both diabetes and hyperlipidemia management, 
together with encouragement of exercise. 
 
 Routine follow up of weight, height and blood pressure.  
Metabolic control assessment by HbA 1c every 3-6 
month and plan for complication detection is needed. 
 
 The association of hyperlipidemia with diabetes 
complications  can be addressed in another study 
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